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SUMMARY 
Refractory cardiogenic shock (CS) is a condition that continues to have a very high mortality 
despite advances in medical therapy. Conventional treatment typically comprises inotrope infusions, 
vasopressors and intra-aortic-balloon-pump (IABP). When circulatory instability is refractory to 
these treatments, mechanical circulatory support represents the only hope for survival, as indicated 
by current guidelines. As most of these patients present with critical circulatory instability requiring 
urgent or emergent therapy, the chosen mechanical assistance should be rapidly and easily 
implanted. For this reason ExtraCorporeal Membrane Oxygenation (ECMO) represents the ideal 
“bridge-to-life” and increasingly it is used to keep the patient alive while the optimal therapeutic 
management is determined (bridge-to-decision). Management may then follow one of three courses: 
“bridge-to-recovery”: patient recovery, and weaning from ECMO; “bridge-to-transplant”: direct 
heart transplantation; “bridge-to-bridge”: placement of ventricular-assist-device or total artificial 
longer-term support. There have been several large reports on the use of ECMO as a mechanical 
support in post-cardiotomy patients but relatively few, mostly small case-series focusing on its role 
in primary acute cardiogenic shock outside of the post-cardiotomy setting. 
 We present the results of our centre’s experience (Padova) in the treatment of primary acute 
cardiogenic shock with the PLS-Quadrox ECMO system (Maquet) as a bridge to decision. 
Furthermore, we evaluated the impact of etiology on patient outcomes by comparing acute primary 
refractory CS secondary to acute myocardial infarction (AMI), myocarditis, pulmonary embolism 
(PE) and post-partum cardiomyopathy (PPCM) with acute decompensation of a chronic 
cardiomyopathy, including dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM) and 
grown-up-congenital-heart-diseases (GUCHD). We also analyzed whether duration and magnitude 
of support may predict weaning and survival. 
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Materials and Methods. Between January 2009 and March 2013, we implanted a total of 249 
ECMO; in this study we focused on 64 patients where peripheral ECMO was the treatment for 
primary cardiogenic shock. Thirty-seven cases (58%) were “acute” (Group A-PCS: mostly acute 
myocardial infarction, 39%), while twenty-seven (42%) had an exacerbation of “chronic” heart 
failure (Group C-PCS: dilated cardiomyopathy 30%, post-ischemic cardiomyopathy 9%, congenital 
3%). 
Results. In group C-PCS, 23 patients were bridged to a LVAD (52%) or heart transplantation 
(33%). In group A-PCS, ECMO was used as bridge-to-transplantation in 3 patients (8%), bridge-to-
bridge in 9 (24%), and bridge-to-recovery in 18 patients (49%). One patient in both groups was 
bridged to conventional surgery. Recovery of cardiac function was achieved only in group A-PCS 
(18 vs 0 pts, p=0.0001). Mean-flow during support ≤60% of the theoretical flow (BSA*2.4) was a 
predictor of successful weaning (p=0.02). Average duration of ECMO support was 8.9 ±9 days. 
Nine patients (14%) died during support; 30-day overall survival was 80% (51/64 pts); 59% of 
patients were discharged, in whom survival at 48 months was 90%. Better survival was observed in 
patients supported for 8 days or less (74% vs 36%, p=0.002). 
Conclusions. In “chronic” heart-failure ECMO represents a bridge to VAD or heart-transplantation, 
while in “acute” settings it offers a considerable chance of recovery, often representing the only 
required therapy. 
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RIASSUNTO 
Lo shock cardiogeno refrattario è una condizione gravata da alta mortalità nonostante i progressi 
nella terapia medica. Il trattamento convenzionale comprende infusione di inotropi, vasopressori, e 
contropulsazione aortica (intra-aortic-balloon-pump – IABP). Quando l’instabilità emodinamica è 
refrattaria a questi trattamenti, il supporto meccanico al circolo rappresenta la sola possibilità di 
sopravvivenza, come indicato dalle attuali linee guida. Tuttavia, poichè la maggior parte di questi 
pazienti si presenta con severa instabilità emodinamica che richiede un intervento urgente o 
emergente, l’assistenza meccanica scelta dovrebbe essere impiantabile in maniera rapida e 
semplice. Per questa ragione, l’ExtraCorporeal Membrane Oxygenation (ECMO) rappresenta 
l’ideale “bridge-to-life”, che sempre più viene usato per supportare le funzioni vitali in attesa che il 
programma terapeutico ottimale venga stabilito (bridge-to-decision). L’iter terapeutico può poi 
seguire tre diversi percorsi: “bridge-to-recovery”: il paziente recupera una funzione 
cardiocircolatoria tale da permettere lo svezzamento dall’ECMO; “bridge-to-transplant”: il paziente 
viene sottoposto a trapianto cardiaco; “bridge-to-bridge”: il paziente viene trattato con impianto di 
un’assistenza ventricolare o di un cuore artificiale totale. Sono state riportate diverse ampie 
casistiche sull’uso dell’ ECMO come supporto meccanico in pazienti con shock dopo intervento 
cardiochirurgico (“post-cardiotomy”), ma relativamente poche serie, e limitate a pochi casi, 
focalizzate sul ruolo dell’ECMO nello shock cardiogeno primario (non post-cardiotomico). 
In questo studio si presenta l’esperienza del centro di Padova nel trattamento dello shock 
cardiogeno primario con il sistema ECMO PLS-Quadrox (Maquet) come bridge-to-decision. 
In particolare, la ricerca proposta si prefigge di valutare l’impatto della differente eziologia 
sull'outcome dei pazienti, paragonando gli shock cardiogeni primari “acuti”, secondari ad infarto 
miocardico acuto, miocardite, embolia polmonare e cardiomiopatia post-partum, con scompensi 
acuti di cardiomiopatie “croniche”, includendo cardiomiopatie dilatative primitive, post-ischemiche, 
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e cardiopatie congenite dell’adulto. Si è infine analizzato se la durata e l’entità del supporto possano 
predire la chance di sopravvivenza e di svezzamento. 
Materiali e metodi. Tra Gennaio 2009 e Marzo 2013, sono stati impiantati con ECMO un totale di 
249 pazienti, di questi 64 erano affetti da shock cardiogeno "primario" (52 uomini e 12 donne, di 
50±16 anni di età) e sono stati trattati con supporto ECMO periferico. Trentasette casi (58%) sono 
stati classificati come "acuti" (Gruppo A, Acuti, IMA 39%, miocardite 6%, embolia polmonare 8%, 
post-partum 2%), mentre i rimanenti 27 (42%) shock erano insorti in un quadro di scompenso 
cardiaco "cronico" (Gruppo B, Cronici, cardiomiopatia dilatativa primitiva 30%, cardiomiopatia 
dilatativa post-ischemica 9%, patologie congenite 3%). 
Risultati della ricerca. Nel gruppo con scompenso cardiaco cronico (Gruppo B), 23 pazienti sono 
stati trattati con impianto o di assistenza ventricolare sinistra (52%) o trapianto cardiaco ortotopico 
(33%). Nel gruppo con scompenso cardiaco acuto (Gruppo A), l' ECMO è stato usato come ponte a 
trapianto in 3 pazienti (8%), come ponte ad impianto di assistenza ventricolare sinistra in 9 pazienti 
(24%) e come ponte al recupero della propria funzionalità cardiaca in 18 pazienti (49%). 
Un solo paziente in ogni gruppo è stato trattato con chirurgia tradizionale. Il recupero della 
funzionalità cardiaca si è osservato solo all'interno del Gruppo A (18 vs. 0 pazienti, p=0,0001). E' 
stato visto che mantenere un flusso medio di supporto ≤60% del flusso teorico (BSA*2,4) 
costituisce un predittore positivo di svezzamento dal dispositivo (p=0,02). Globalmente, la durata 
media del supporto ECMO è stata di 8,9±9 giorni. Nove pazienti (14%) sono deceduti durante il 
supporto ECMO; la sopravvivenza globale a 30 giorni è stata dell' 80% (5/64 pazienti); il 59% dei 
pazienti è stato dimesso dall’ ospedale e, tra questi, la sopravvivenza a 48 mesi è stata del 90%, 
senza differenze significative nei due gruppi. La sopravvivenza migliore si è osservata in quei 
pazienti che hanno necessitato di supporto ECMO per un periodo inferiore o uguale ad 8 giorni 
(74% vs. 36%, P=0,002). 
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In conclusione nei pazienti con shock cardiogeno refrattario nell'ambito di uno scompenso cardiaco 
cronico l'ECMO rappresenta un dispositivo-ponte verso l'impianto di assistenza ventricolare sinistra 
o verso trapianto cardiaco. Nei pazienti con shock refrattario dovuto ad eziologia acuta, invece, tale 
supporto offre sostanziali chance di recovery, costituendo spesso l'unica terapia necessaria. 
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1. CARDIOGENIC SHOCK (CS) 
1.1 INTRODUCTION 
Cardiogenic shock (CS) is a common endpoint of multiple disease processes that is characterized by 
myocardial dysfunction, depressed cardiac output (CO) and end-organ hypoperfusion. CS is 
associated with significant morbidity and mortality, and conventional medical support such as 
inotropic agents or intra-aortic balloon counterpulsation is often insufficient to reverse the 
hemodynamic changes seen in CS [1].  
Recent research has suggested that the peripheral vasculature and neurohormonal and cytokine 
systems play a role in the pathogenesis and persistence of CS. 
Advances in management, including early revascularization, have led to a reduction of in-hospital 
mortality of more than 10% [1-2]. A further reduction may be seen with the advancement of 
mechanical circulatory support (MCS), which provides a means for patients to recover or transition 
to long-term therapies for management of their underlying cardiac disease. In particular, the 
development of percutaneous MCS options has facilitated rapid resuscitation of the cardiogenic 
shock patient, potentially interrupting the characteristic systemic inflammatory response before it 
can cause irreversible harm. 
 
1.2 DEFINITION, DIAGNOSIS AND CAUSES OF CARDIOGENIC SHOCK 
Cardiogenic shock is a state of end-organ hypoperfusion due to cardiac failure. The definition of CS 
includes hemodynamic parameters: persistent hypotension (systolic blood pressure <90 mmHg or 
mean arterial pressure 30 mmHg lower than baseline) with severe reduction in cardiac index (<1.8 
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l/min/m
2 
without support or <2.0 to 2.2 l/min/m
2
 with support) and adequate or elevated filling 
pressure (eg, left ventricular [LV] end-diastolic pressure >18 mmHg or right ventricular [RV] end-
diastolic pressure >10 to 15 mm Hg). Hypoperfusion may be manifest clinically by cool 
extremities, decreased urine output, and/or alteration in mental status. Hemodynamic abnormalities 
form a spectrum that ranges from mild hypoperfusion to profound shock, and the short-term 
outcome is directly related to the severity of hemodynamic derangement. In recent studies of 
cardiogenic shock, eligibility criteria included systolic blood pressure <90 mmHg for >30 min or 
requirement of catecholamines to maintain systolic pressure >90 mmHg, plus clinical signs of 
pulmonary congestion and impaired organ perfusion with at least one of the following criteria: (I) 
altered mental status; (II) cold, clammy skin and extremities; (III) oliguria with urine output <30 
mL
-1
; or (IV) serum lactate >2.0 mmol L
-1
. 
The diagnosis is usually made with the help of pulmonary artery (PA) catheterization; however, 
Doppler echocardiography may also be used to confirm elevation of LV filling pressures. 
Cardiogenic shock often occurs as the result of an acute event that precipitates rapid cardiovascular 
collapse. Myocardial infarction (MI) with LV failure remains the most common cause of CS. 
Among patients with an acute ST-elevation myocardial infarction (MI), 8% will develop 
cardiogenic shock [2] typically within 24 h of the onset of symptoms [3]. In these patients, 
cardiogenic shock is typically a direct consequence of regional myocardial dysfunction and 
diminished contractility. Mechanical complications of MI including ventricular septal defect, 
papillary muscle rupture producing acute mitral regurgitation, and free left ventricular wall rupture 
can also cause cardiogenic shock. Echocardiography is the technique of choice to rule out these 
entities and should be performed early unless the diagnosis is extensive anterior MI and the patient 
is undergoing prompt percutaneous coronary intervention (PCI). In addition, the detection of 
valvular disease before angiography may alter the revascularization approach.  
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Hemorrhage, infection, and/or bowel ischemia may contribute to shock in the setting of MI. As with 
mechanical complications, a high index of suspicion is required to make these diagnoses in MI 
patients, and survival may depend on timely recognition and treatment. 
Any cause of acute, severe left ventricle (LV) or right ventricle (RV) dysfunction may lead to CS. 
Many non-ischemic disease processes may present acutely or subacutely and result in cardiogenic 
shock. Acute valvular regurgitation, regardless of cause, can rapidly progress to severe heart failure. 
Several types of cardiomyopathies can present with a fulminant course, including viral myocarditis, 
giant-cell myocarditis, peripartum and Takotsubo cardiomyopathy. Extracardiac disease may also 
result in CS, as with a massive pulmonary embolism or pericardial tamponade. Finally, 3–4% of 
patients admitted to the hospital for acute decompensation of chronic heart failure will present with 
shock [4]. 
 
1.3 INCIDENCE 
After decades of remarkable stability in the incidence of CS, it appears that the incidence is on the 
decline in parallel with increasing rates of use of primary PCI for acute MI. CS continues to 
complicate approximately 5% to 8% of STEMI and 2.5% of non-STEMI cases [5]. This translates 
to 40000 to 50000 cases per year in the United States [6]. The routine use of troponin to define non-
STEMI will result in a drop in this percentage as more MIs are detected but will not alter the total 
number of cases of CS. 
The only way to prevent CS appears to be very early reperfusion therapy for MI. A randomized trial 
of early, in-ambulance thrombolysis versus primary PCI found no CS among patients assigned to 
prehospital thrombolysis [7]. Among PCI-assigned patients, just 0.5% developed CS in the group 
randomized <2 hours from symptom onset. A major focus of public health campaigns is the very 
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early recognition and reperfusion of MI, which should reduce CS incidence. Risk factors for 
development of CS in the context of MI include older age, anterior MI, hypertension, diabetes 
mellitus, multivessel coronary artery disease, prior MI or angina, prior diagnosis of heart failure, 
STEMI, and left bundle-branch block [8]. There may be clues to impending shock: heart rate is 
higher and blood pressure lower on hospital presentation among patients who develop CS after 
admission. 
 
1.4 PATHOPHYSIOLOGY 
Cardiogenic shock is the result of temporary or permanent derangements in the entire circulatory 
system. LV pump failure is the primary insult in most forms of CS, but other parts of the circulatory 
system contribute to shock with inadequate compensation or additional defects. 
With the exception of acute valvular disease, CS typically occurs in the setting of pronounced 
myocardial dysfunction and low CO. The reduction in MAP results in poor systemic perfusion and 
end-organ ischemia. Low coronary perfusion pressure may exacerbate ischemia. Catecholamine 
release attempts to compensate for the low-output state by increasing inotropy and peripheral 
vasoconstriction at the cost of increasing myocardial oxygen demand. Up-regulation of pressure but 
worsening congestion. There are increased cytokine levels and expression of inducible nitric oxide 
synthase [2], which can exacerbate hypotension and further worsen myocardial function, causing a 
deterioration of cardiovascular hemodynamics. 
The degree of myocardial dysfunction that initiates CS is often, but not always, severe. LV 
dysfunction in shock reflects new irreversible injury, reversible ischemia, and damage from prior 
infarction. The unique position of the heart as an organ that benefits from low blood pressure via 
afterload reduction and also suffers from low blood pressure via compromise of coronary flow 
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creates a situation in which changes in 
hemodynamics may be simultaneously 
beneficial and detrimental. 
As depicted in Figure 1, a decrease in 
coronary perfusion lowers cardiac output 
(CO), which further decreases perfusion of 
the heart and other vital organs. Coronary 
flow may be additionally compromised by atherosclerosis of vessels other than the infarct artery. 
Metabolic derangements occur in the remote myocardium and in the infarct region [9]. 
Hypoperfusion causes release of catecholamines, which increase contractility and peripheral blood 
flow, but catecholamines also increase myocardial oxygen demand and have proarrhythmic and 
myocardiotoxic effects. Inotropic agents and vasoconstrictors temporarily improve CO and 
peripheral perfusion but do not interrupt this vicious circle. Rapid intra-aortic balloon pump (IABP) 
support may temporarily relieve ischemia and support the circulation, but IABP is not definitive 
therapy. Relief of coronary occlusion, best achieved through PCI or surgery, interrupts the vicious 
circle and saves lives. RV dysfunction may cause or contribute to CS. Predominant RV shock 
represents only 5% of cases of CS complicating MI [10]. RV failure may limit LV filling via a 
decrease in CO, ventricular interdependence, or both. Treatment of patients with RV dysfunction 
and shock has traditionally focused on ensuring adequate right-sided filling pressures to maintain 
CO and adequate LV preload; however, patients with CS due to RV dysfunction have very high RV 
end-diastolic pressure, often >20 mmHg [10]. This elevation of RV end-diastolic pressure may 
result in shifting of the interventricular septum toward the LV cavity, which raises left atrial 
pressure but impairs LV filling due to the mechanical effect of the septum bowing into the LV. This 
alteration in geometry also impairs LV systolic function [11]. Therefore, the common practice of 
aggressive fluid resuscitation for RV dysfunction in shock may be misguided. Inotropic therapy is 
Figure 1: Reynolds et al. 
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indicated for RV failure when CS persists after RV end-diastolic pressure has been optimized. RV 
end-diastolic pressure of 10 to 15 mmHg has been associated with higher output than lower or 
higher pressures [12] but marked variability exists in optimal values. Inhaled nitric oxide (NO) may 
be useful to lower pulmonary vascular resistance and promote forward flow. Both pericardiectomy 
and creation of atrial septal defects have been used in extreme cases.  
Shock due to isolated RV dysfunction carries nearly as high a mortality risk as LV shock [10]. The 
benefit of revascularization was similar in the SHOCK registry for patients with primarily RV 
versus primarily LV dysfunction. 
Hypoperfusion of the extremities and vital organs is a hallmark of CS. The decrease in CO caused 
by MI and sustained by ongoing ischemia triggers release of catecholamines, which constrict 
peripheral arterioles to maintain perfusion of vital organs. Vasopressin and angiotensin II levels 
increase in the setting of MI and shock, which leads to improvement in coronary and peripheral 
perfusion at the cost of increased afterload, which may further impair myocardial function. 
Activation of the neurohormonal cascade promotes salt and water retention; this may improve 
perfusion but exacerbates pulmonary edema. The reflex mechanism of increased systemic vascular 
resistance (SVR) is not fully effective. These findings are consistent with the observation that MI 
can cause the systemic inflammatory response syndrome (SIRS) and suggest that inappropriate 
vasodilation as part of SIRS results in impaired perfusion of the intestinal tract, which enables 
transmigration of bacteria and sepsis. SIRS is more common with increasing duration of shock [13] 
even though levels of interleukin-6 and tumor necrosis factor-α have been found to be elevated on 
admission among MI patients who were initially in Killip class I and later developed CS [14]. 
Cytokine levels rise more dramatically over the 24 to 72 hours after MI. Tumor necrosis factor-α 
and interleukin-6 have myocardial depressant action. Tumor necrosis factor-α also induces coronary 
endothelial dysfunction, which may further diminish coronary flow [15]. Other circulating factors 
(complement, procalcitonin, neopterin, C-reactive protein, and others) have been reported to 
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contribute to SIRS in CS. Excess NO may also contribute to SIRS. MI is associated with increased 
expression of inducible NO synthase, which leads to excess NO, which causes vasodilation, 
myocardial depression, and interference with catecholamine action. 
Cardiogenic shock has been divided into four stages to demonstrate severity and progression of 
disease: preshock, mild shock, profound shock and severe refractory CS [16]. The progression from 
mild cardiogenic shock to severe refractory cardiogenic shock reflects the severity of hemodynamic 
compromise and is reflected by the number of vasoactive medications required to maintain 
reasonable CO and MAP. In mild shock, the cardiovascular system may not require support or can 
be easily supported with low doses of one inotrope or vasopressor. Patients with profound shock 
require moderate-to-high doses of a single agent, whereas patients with severe refractory 
cardiogenic shock remain hemodynamically compromised, despite high doses of multiple 
vasoactive medications. Mortality increases progressively with each stage, and patients with severe 
refractory cardiogenic shock generally have a very poor prognosis in the absence of MCS. 
However, cardiogenic shock is not a mere decrease in cardiac contractile function, but also a 
multiorgan dysfunction syndrome (MODS) resulting from peripheral hypoperfusion with 
microcirculatory dysfunction, often complicated by a systemic inflammatory response syndrome 
(SIRS) and sepsis [17,18-23]. 
Once MODS has developed, it is difficult to improve prognosis and reduce mortality by simply 
increasing cardiac output with a circulatory assist device. Prevention of MODS may depend on 
three critical factors: 
(1) optimal timing (i.e. early initiation) of mechanical circulatory support, 
(2) optimal level of mechanical circulatory support with reestablishment of adequate perfusion of 
critical organs, and 
(3) optimal prevention and management of potential device-related complications (i.e. device 
malfunction, infection). 
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Intuitively, one would expect that haemodynamic parameters would best discriminate between 
survivors and non-survivors, and at least for the calculated pressure-flow-product ‘cardiac power 
output/index’, this has been demonstrated [24,25]. However, in the IABP-Shock study [20], cardiac 
index itself was unrelated to patient survival beyond the first 24 h of CSMI. Likewise, biomarkers 
of heart failure (e.g. BNP) were unrelated to prognosis in the first 96 h of CSMI. 
On the other hand ,MODS severity (as indicated by the APACHE II or SAPS II scores) and 
biomarkers of SIRS (like Interleukin 6 and receptor of advanced glycation end-products, RAGE) 
can predict mortality more accurately than haemodynamic indices [26]. 
Although LV contractile failure and low cardiac output are the primary cause of cardiogenic shock, 
improving cardiac output alone may not reverse or even halt the progression of MODS if initiated 
too late. Therefore, the haemodynamic improvement of cardiac index may be a measure of technical 
success of mechanical circulatory support; however, without limiting the progression of SIRS and 
MODS within the first few days, these haemodynamic improvements may be futile and may not 
translate into improved survival. 
 
1.5 INITIAL MANAGEMENT OF CARDIOGENIC SHOCK  
The initial management goals of cardiogenic shock include cardiovascular resuscitation and 
identification of the underlying cause. Reversible cardiac causes, including arrhythmias and 
conduction disturbances, should be identified and treated. If myocardial ischemia or infarction is 
suspected, patients should rapidly undergo coronary angiography and either percutaneous or 
surgical revascularization. In the SHOCK (One-year survival following early revascularization for 
cardiogenic shock) trial, early revascularization in those presenting with cardiogenic shock reduced 
1-year mortality from 66 to 53% [27]. Medical therapy of cardiogenic shock is directed at 
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normalizing hemodynamic parameters, correcting metabolic disarray and minimizing end-organ 
dysfunction. Vasoactive agents (inotropes, vasopressors) are often required to augment CO but at 
the expense of worsening myocardial oxygen demand, exacerbation of ischemia and potentiation of 
arrhythmias. Correction of acidosis may help to prevent damage to end-organs and to promote the 
effects of vasoactive agents. Those patients with continued worsening or lack of improvement of 
hemodynamics despite escalation of medical therapy are considered to have severe refractory shock 
and should immediately be considered for placement of MCS. 
 
1.6 MECHANICAL CIRCULATORY SUPPORT IN THE TREATMENT OF 
CARDIOGENIC SHOCK 
The key concept is to quickly identify patients in need of more support than medical management 
and/or an IABP can achieve, as early intervention with MCS in the patients at highest risk is most 
effective when done early. MCS can interrupt the inflammatory cascade initiated by the onset of 
shock and prevent progression to irreversible end-organ damage and subsequent death; however, 
there remains a window of opportunity during which rescue is possible. An IABP is typically the 
first line of mechanical support used due to ease of insertion and minimal risk, but it is often 
insufficient in providing adequate support in patients with severe cardiogenic shock. Other options 
for temporary support include the Impella
TM
 percutaneous ventricular assist device (PVAD), 
TandemHeart
TM
 PVAD, venoarterial extracorporeal membrane oxygenation (V-A ECMO) and the 
CentriMag
TM
 device, which can be placed surgically or percutaneously. (Figure 2) [28].  
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Figure 2: Sayer et al. 
 
Device selection is based on a number of factors including the degree of hemodynamic support 
needed, whether right ventricular failure or lung injury is present, individual patient factors (e.g. 
mechanical valves, peripheral vascular disease) and the availability of interventionalists/cardiac 
surgeons. 
Ouweneel and Henriques
 
[29] defined the ‘ideal device for cardiogenic shock’ as follows: ‘ . . . 
during an acute critical presentation only those assist devices allowing percutaneous access are 
suitable due to the invasiveness of surgical devices. The ideal device should enable both 
haemodynamic support and myocardial protection. Also, a percutaneous approach is preferable to 
provide for a quick and easy deployment. In addition, the ideal device should be associated with a 
low complication rate, as complications may sometimes outweigh the potential beneficial effect. 
Complications associated with any (percutaneous) LV assist device may include limb ischaemia, 
embolisation of atherosclerotic and/or thrombotic material, stroke, infection and haemolysis’.  
In line with these demands for mechanical circulatory support in CS, different technical strategies 
have been developed over the past decades to improve cardiac output and unload the critically 
damaged left ventricle by either afterload or pre-load reduction (i.e. pressure or volume unloading, 
respectively). Additionally, circulatory support may be provided to the left ventricle alone, the right 
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ventricle alone, or to both ventricles. Biventricular assist devices may be combined with 
replacement of pulmonary gas exchange (i.e. extracorporal membrane oxygenation, ECMO) or be 
administered as pure right and left ventricular haemodynamic support.  
Based on the different physiological concepts outlined above, we distinguish among three 
categories of peripheral/percutaneous circulatory support devices in CS: 
(1) mechanical LV support by LV pressure unloading [30]—the IABP; 
(2) mechanical LV support by LV volume unloading [30]—the TandemHeartTM, the Impella 
Recover LP
®
 micro-axial rotary pump; 
(3) mechanical circulatory support with membrane oxygenation [30]—ECMO; 
The possibilities are completed by surgically implanted mechanical support -without simultaneous 
replacement of pulmonary gas exchange- combining right (RVAD) and/or left (LVAD) 
paracorporeal ventricular assist device therapy. 
 
1.7 INTRA-AORTIC BALLOON PUMP (IABP) 
The IABP (Figure 3) is the most commonly used form of MCS, it’s a 
balloon inserted in the descending aorta that augments coronary blood flow 
by inflating during diastole, while also assisting myocardial function 
through reduced afterload by deflating during systole. The ultimate effect is 
limited to an increase of LV stroke volume and cardiac output by up to 1 
l/min (15–30%, respectively). The haemodynamic effects of IABP in CS 
[31] include: 
 an increase in stroke volume and CO, 
Figure 3: Werdan et al. 
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 an increase in systemic blood pressure with increased coronary blood flow in open coronary 
arteries, [32] 
 a reduction in LV pre-load, LV end-diastolic pressure, and pulmonary capillary wedge 
pressure, 
 a decrease in LV wall stress and myocardial oxygen demand, and 
 improved reperfusion after thrombolysis in STEMI patients. 
Outcomes data using the IABP are scarce. In the randomized, prospective, open-label, multicentre 
IABP SHOCK II Trial [17], a total of 600 patients with CSMI were assigned—after best medical 
therapy and early revascularization, predominantly with PCI (95.8%)—to additional intra-aortic 
balloon counterpulsation (IABP group, 301 patients) or no intra-aortic balloon counterpulsation 
(control group, 299 patients). No difference was found in the primary endpoint—30-day all-cause 
mortality—with 39.7% mortality in the IABP group and 41.3% mortality in the control group 
(relative risk with IABP 0.96, 95% confidence interval 0.79–1.17, P=0.69). The authors concluded 
that the use of IABP did not significantly reduce 30-day mortality in patients with CSMI for whom 
an early revascularization strategy was planned. 
However, despite lingering questions about the efficacy of IABP therapy, it remains the first-line 
therapy for the treatment of cardiogenic shock at most centers. 
Recommendations for the use of intra-aortic balloon pump in patients with cardiogenic shock 
There is a large indication list for the adjunctive use of IABP in heart failure and shock states 
including cardiac surgery [31], with little convincing evidence of proven benefit. On the other hand, 
those indications with evidence from large RCTs are all negative: (I) CSMI, (II) elective high-risk 
PCI in patients with LV dysfunction and extensive coronary artery disease [33], and (III) acute 
anterior STEMI without cardiogenic shock [34]. 
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The American College of Cardiology/American Heart Association STEMI guidelines recommend 
the use of IABP as a class IIa indication for patients with CSMI [35], whereas the recent European 
guidelines state that ‘intra-aortic balloon pumping may be considered (IIb/B)’ (Figure 10) [30].
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1.8 TANDEMHEART PERCUTANEOUS VENTRICULAR ASSIST DEVICE 
The TandemHeart PVAD (Cardiac Assist, Inc., Pittsburgh, Pennsylvania, 
USA) (Figure 4) is an external centrifugal blood pump with percutaneous 
cannulae. Oxygenated blood is aspirated from the left atrium and injected 
into the lower abdominal aorta or iliac arteries via a femoral artery 
cannula. The inflow cannula is placed in the left atrium via a transseptal 
puncture. Pump outflow is returned to the body through a 17 French 
cannula in the femoral artery (Figure 5). It typically augments CO up to 
3.0–4.0 l/min. The haemodynamic effects of the TandemHeart are 
superior to the IABP [35-38] leading to a greater increase in CO and MAP 
and a decrease PCWP, central venous pressure, and pulmonary artery 
pressure, resulting in reduced filling pressures in the left and right 
ventricle, reduced cardiac workload and reduced oxygen demand 
[35,39], as well as an increase 
in cardiac power index. 
Its use is limited by access site complications, limb ischemia 
and bleeding. Implantation is more time-consuming and 
requires specialized expertise, due to the need for a 
transseptal puncture. The presence of a cannula in the left 
atrium can be a nidus for thrombus formation. One 
significant advantage of the TandemHeart is that it can be 
configured to provide right ventricular support with inflow cannula placement into the right atrium 
and outflow cannula placement into the main pulmonary artery [40]. The TandemHeart is FDA-
approved for up to 6h of use, but successful use has been reported for greater than 1 week [41]. In 
Figure 5: Srihari et al. 
Figure 4: Werdan et al. 
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the largest reported series, 117 patients with refractory cardiogenic shock were implanted with the 
TandemHeart for an average of 5.8 days [42]. The population was critically ill, with a MAP of 
45mmHg, cardiac index of 0.5 l/min/m2 , and lactic acid level of 24.5 mg/dl. TandemHeart support 
provided rapid reversal of the hemodynamic abnormalities, increasing the MAP to 81mmHg, 
cardiac index to 3.0 l/min/m2 , and decreasing the lactic acid level to 11.0 mg/dl. Although there 
was no control group, the 30-day mortality of 40% was considerably better than expected outcomes 
in this population. The most common complications were bleeding and sepsis. 
Recommendations for the use of the TandemHeart in patients with cardiogenic shock 
In the European guidelines a class IIB recommendation is given for LV assist devices in CSMI [43] 
(Figure 6). The 2013 AHA/ACCGuideline for the Management of ST-Elevation Myocardial 
Infarction assigns a level IIb/C indication for LV assist devices in refractory cardiogenic shock. 
This includes centrifugal pumpsystems such as the TandemHeart and ECMO [35]. 
 
Figure 6: ESC GL for the management of STEMI [43] 
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1.9 IMPELLA RECOVER PERCUTANEOUS VENTRICULAR ASSIST DEVICE 
The Impella Recover PVAD (AbioMed Inc, Danvers, 
Massachusetts, USA) is a micro-axial rotary pump positioned across 
the aortic valve to provide active support by transvalvular LV 
assistance, expelling aspirated blood from the left ventricle into the 
ascending aorta (Figure 7).  
Two versions are currently available: the Impella Recover LP 2.5 
can provide up to 2.5 L min
-1
 and can be inserted percutaneously. 
The Impella Recover LP 5.0 can deliver up to 5.0 L min-1 but 
requires surgical cutdown of the femoral or axillary artery. 
The Impella 2.5 is an axial flow motor that pumps blood from the left ventricle into the ascending 
aorta. The catheter is placed percutaneously through a tapered 13 or 14 French sheath and is 
connected to an external power source. Flow is less robust than the Tandem-Heart, averaging less 
than 2.5 l/min. However, implantation is quicker and there are fewer access site complications due 
to the smaller sheath size. A comparison of the Impella 2.5 with IABP showed better initial 
hemodynamic support with the Impella PVAD, but no difference in mortality or support after 6h 
[44]. The primary complication of the Impella 2.5 is hemolysis, which can be severe and often 
limits the duration of use. Another common issue is pump migration from its intended position, 
which may lead to poor support or contribute to hemolysis. 
The Impella 5.0 is a larger device, providing flows up to 5.0 l/min. Due to its size, it must be 
implanted surgically, either directly into the ascending aorta or through a vascular graft to the 
femoral or axillary artery. Due to the larger size of the inflow, hemolysis is a less frequent 
complication.  
Figure 7. 
22 
 
Several studies have demonstrated that the Impella device is safe and haemodynamically effective 
in STEMI and high-risk PCI patients [29]. The unloading of the left ventricle is associated with 
reduced end-diastolic wall stress and an immediate decrease in PCWP [29]. Coronary perfusion 
pressure and coronary flow are reported to be increased and myocardial oxygen consumption 
reduced [29]. 
With respect to the role of the Impella pump in cardiogenic shock and especially in CSMI, the 
multicentre Impella EUROSHOCK-Registry [45] included 120 patients with CSMI receiving 
temporary circulatory support with the Impella- 2.5-pLVAD. Thirty-day mortality was 64.2%. After 
Impella-2.5- pLVAD-implantation, lactate levels significantly decreased from 5.8±5.0 to 2.5±2.6 
mmol L
-1
 (p = 0.023) at 48 h.  
The ISAR-SHOCK randomized trial compared the Impella 2.5 with the IABP in cardiogenic shock 
patients [46] As showed in this study, CI and MAP increased more in the Impella group; 
furthermore, serum lactate levels were lower in the Impella group than in the IABP group. No 
differences in mortality, major bleeding, distal limb ischaemia, arrhythmias, and infections were 
found. 
It has been suggested that, in severe cardiogenic shock, the Impella 5.0 device may provide superior 
haemodynamic support [29,47]. A lower mortality rate has been reported for Impella 5.0 in patients 
with post-cardiotomy low-output syndrome with a residual CO of 1 L min
-1
 vs. IABP [48,49] 
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1.10 CENTRIMAG VENTRICULAR ASSIST DEVICE 
The Thoratec CentriMag VAD (Thoratec Corporation, Pleasanton, California, USA) (Figure 8) is a 
centrifugal pump with a magnetically levitated rotor that can provide up to 10 l/min of blood flow. 
The CentriMag can be connected to many different types of circuits, including ECMO, but is 
designed as an extracorporeal, surgically implanted VAD for short-term or intermediate-term 
support. For left ventricular support, an inlet cannula is placed in the left ventricular apex (the left 
atrium is not recommended due to the potential for thromboembolic complications) with the outlet 
cannula delivering blood to the aorta. The CentriMag can also provide right ventricular support with 
inflow from the right atrium and outflow into the pulmonary artery. Two CentriMags can also be 
configured to provide biventricular support.  
 
Figure 8. Kaczorowski et al. 
 
The primary advantage of the CentriMag system is its ability to deliver high-flow rates and to 
completely unload the LV. The system is relatively easy to use and has a low rate of 
thromboembolism when high-flow rates are maintained The CentriMag is  more durable than 
PVADs and can provide effective support for weeks to months [50]. A multicenter investigation of 
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the CentriMag in 38 patients demonstrated a 47% 30-day survival. The major complications 
included infection and neurological dysfunction [51]. The CentriMag can be configured to support 
the right ventricle percutaneously with an inflow cannula placed in the right atrium via the femoral 
vein and the outflow cannula placed in the pulmonary artery via the internal jugular vein [52]. 
 
1.11 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 
The complete ECMO system (Figure 9)—a modified heart–lung machine—generally consists of a 
centrifugal pump, a heat exchanger, and a membrane oxygenator. Venous desaturated blood is 
aspirated from the right atrium into a centrifugal pump through canulla inserted into the right 
atrium. The pump outflow is directed into a membrane oxygenator and is guided via an outflow 
cannula into the aorta or femoral/axillary artery.  
Figure 9. Westaby et al. 
 
Veno-Arterial (V-A) ECMO can provide support for patients with lung injury as well as either 
univentricular or biventricular failure. It’s has been applied in STEMI [53], myocarditis [54], post-
cardiotomy [55], interhospital transfer [56,57] and also in the cardiac catheterization laboratory in 
patients who developed cardio-respiratory arrest during PCI and TAVI [58]. 
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In the most commonly used percutaneous configuration, the inflow cannula is inserted into the right 
atrium through either the femoral or jugular vein and the outflow cannula is placed in the lower 
descending aorta via the femoral artery. Due to the large size of the arterial cannula (18 French), an 
antegrade catheter is often placed in the ipsilateral femoral artery to provide adequate perfusion to 
the leg. A percutaneous circuit can be established in less than 30 min, and it is feasible to put 
patients on ECMO at the bedside during an emergency. When percutaneous access is not possible, 
the ECMO circuit can be placed centrally, with direct cannulation of the right atrium and aorta. 
Of the percutaneous MCS options, ECMO provides the most cardiac support, with the ability, based 
on cannula size and position, to achieve flow of greater than 6.0 l/min. However, ECMO is resource 
intensive, requiring continuous monitoring by nursing and trained perfusion staff. Complications 
include limb ischemia, bleeding, stroke, and infection. Adequate levels of anticoagulation must be 
maintained to prevent thromboembolic complications. In patients with pulsatility during support, 
care must be taken to ensure that blood leaving the heart is adequately oxygenated, as perfusing the 
coronary arteries and brain with deoxygenated blood may result in catastrophic anoxic injury. 
Alternatively, with severe ventricular dysfunction, the left ventricle (LV) may not be adequately 
decompressed due to return of blood to the left atrium through the bronchial circulation. Left 
ventricular distension can lead to excess wall stress and may impede ventricular recovery. Several 
methods of decompressing the LV have been described, including a transseptal catheter [59], a 
pulmonary artery cannula [60], and minimally invasive placement of an apical vent [61]. Several 
recent reports have described successful use of an Impella Recover 2.5 as a vent for the LV [62-64]. 
Following institution of ECMO, there is often a rapid reversal of hemodynamics with a decrease in 
inotrope/vasopressor requirement, improvement in gas exchange, and reduction in markers of 
endorgan failure. With meticulous care, ECMO support can be maintained for weeks. 
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Recommendations for the use of ECMO in patients with cardiogenic shock 
There is a class IIb/C recommendation in the European STEMI guidelines [43] to consider an LV 
assist device for circulatory support in patients with refractory cardiogenic shock (Figure 10). The 
European guidelines on myocardial revascularization recommend considering— without a definite 
recommendation—ECMO implantation for temporary support in CSMI patients who continue to 
deteriorate due to inadequate circulatory support of the IABP. This recommendation is based on 
expert consensus. 
 
Figure 10: Werdan et al. 
 
1.12 CONCLUSIONS 
Despite optimal up-to-date therapy of CS, mortality continues to remain unacceptably high. Limited 
data may support the use of levosimendan [65] but innovations in pharmacological therapy are not 
forthcoming. Mild therapeutic hypothermia is promising as a potential therapeutic strategy for 
CSMI [66]. It has multiple potentially beneficial effects, including the potential to improve post-
ischaemic cardiac function and haemodynamics, decrease myocardial damage, and reduce end-
organ injury from prolonged hypoperfusion. The neutral results of the IABP-SHOCK II Trial 
remind us that immediate haemodynamic improvement may not automatically translate into 
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improved survival. In view of the dissociation between improvements in haemodynamic parameters 
and clinical outcomes, including mortality, device therapy may be the best therapy for the future. 
In fact mechanical circulatory support not only improves haemodynamics, but prevent or reduce 
MODS and ultimately, mortality. 
However clinical success of device therapy in CS does not depend on the mechanical qualities of 
the device alone. The ease and safety of device implantation—especially under emergency 
conditions and during cardiopulmonary resuscitation—will also greatly influence patient outcome. 
Additionally, the rates of device-related complications such as limb ischaemia, access site bleeding, 
haemolysis, and infection are still too high, and the contact of blood with these devices may 
cause/worsen SIRS and MODS. Patients with CS have minimal reserve to tolerate operator error or 
device complications.  
Data from morbidity studies with a focus on the time course of SIRS and MODS development 
indicate that haemodynamic support has limited ability to change outcome if initiated when overt 
MODS has already developed. Mechanical circulatory support should not be considered the 
treatment of last resort for CS, but should probably be initiated early in the disease course to 
minimize the negative effects of high-dose catecholamine therapy on microcirculation and before 
end-organ dysfunction with MODS.  
Finally among the other mechanical circulatory support devices for CS, we believe that ECMO is 
likely to have the greatest potential for wider clinical use.  
Its major advantages are: 
 quick and easy percutaneous insertion of inflow and outflow cannulas, 
 full circulatory support with up to 4.0 L min-1,  
 ECMO rapidly improves tissue oxygenation in situations of cardiogenic shock combined 
with severe pulmonary oedema. 
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2.EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 
2.1 INTRODUCTION 
Since the first successful application of the heart–lung machine in 1953 by John Gibbon [1], great 
efforts havebeen made to modify the bypass techniques and devices in order to allow prolonged 
extracorporealcirculation in the intensive care unit (ICU), commonly referred to as extracorporeal 
membrane oxygenation(ECMO). It is instituted for the management of life threatening pulmonary 
or cardiac failure (or both), when no other form of treatment has been or is likely to be successful. 
ECMO uses classic cardiopulmonary bypass technology to support circulation. It provides 
continuous, non-pulsatile cardiac output and extracorporeal oxygenation [2] and it is used as 
temporary support, usually awaiting recovery of organs. 
At the time, Gibbon’s invention was revolutionary and propelled the field of cardiac surgery. 
Although Gibbon’s creation allowed for the care of the cardiac patient in the operating room, its 
applicability outside the operating theater was largely unimaginable at the time. Eventually, the 
need to provide mechanical circulatory support (MCS) expanded outside the operating room, 
resulting in the development of extracorporeal membrane oxygenator (ECMO) technology. 
However, innovations in the MCS field progressed, leading to the development of smaller 
implantable pumps compact enough to be inserted through a peripheralvessel but powerful enough 
to maintain end-organ perfusion. 
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2.2 HISTORY AND DEVELOPMENT OF OXYGENATORS 
Extracorporeal oxygenators are artificial devices that substitute for anatomical lungs by delivering 
oxygen to, and extracting carbon dioxide from, blood. They were first conceptualised by the 
English scientist and philosopher Robert Hooke (1635–1703) who demonstrated experimentally in 
1667 that inflation and deflation of the lungs of an animal was not mandatory for the oxygenation of 
the blood flowing through them. He also speculated as to ‘whether suffering the blood to circulate 
through a vessel, so that it may be openly exposed to the fresh air [might] not suffice for the life of 
an animal’ without using the lungs for oxygenation [3,4].The artificial oxygenation and perfusion of 
individual organs was an objective of early 19th century physiologists. Julien-Jean Cesar le Gallois 
failed in his attempts to perfuse isolated decapitated rabbits by the injection of arterial blood in 1812 
because of coagulation [5] but, following the description of the method of defibrinating blood by 
Prevost and Dumas in 1821 [6], Lobell [7] successfully perfused an isolated kidney by injecting 
arterial blood in 1849. In 1858, Brown-Sequard perfused the head of a dog with moderate success 
by injection, and showed that 5 min of ischaemia of the brain resulted in death of the organ [8,9]. 
The first ‘direct contact’ artificial oxygenation of blood in an extracorporeal circulation was 
achieved in 1869 byLudwig and Schmidt [10] by shaking together defibrinated blood with air in a 
balloon. Further development of‘direct-contact’, ‘three-dimensional’ extracorporeal oxygenation of 
blood was the perfusion of an isolated kidney in 1882 by Schroder of Strasburg, using the first 
simple‘bubble oxygenator’ [4,8,11,12] and, from the same laboratory in 1882, Frey and Gruber 
described the first‘two-dimensional’, direct-contact extracorporeal oxygenator that exposed a thin 
film of blood to air in an inclined cylinder which was rotated at a frequency of 30 min
-1
 by an 
electric motor [4,8,12,13]. 
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Several bubble and surface type oxygenators were developed in the first two decades of the 20th 
century [12]. For example, Hooker described in 1910 a bubble oxygenator [12,14] and in 1915 a 
film oxygenator in which blood flowed over a single rotating disc to be oxygenated [12,13]. 
Richards and Drinker described anoxygenator in 1915 that incorporated a perforated silk screen 
through which the blood flowed [12,16]. 
The problem of reliably preventing coagulation in perfusion was solved by the 1916 discovery of 
heparin by Jay Maclean. Maclean, a medical student working in the laboratory of W. H. Howell at 
the John Hopkins University at Baltimore, demonstrated that a phosphatide (cuorin) extracted from 
canine heart muscle prevented coagulation of the blood [4,8,17]. Subsequently, it was discovered 
that the active substance could also be extracted from dog liver in reasonable quantities and it was 
given the name ‘heparin’ [8,18]. The discovery of the anticoagulant property of heparin paved the 
way to the development of whole body perfusion in animals and, subsequently, extracorporeal 
oxygenators for use in human cardiac surgery [4,8]. 
The first whole body extracorporeal perfusion with isolation of the heart was, in fact, demonstrated 
in a canine model by the Russian scientists Brukhonenko and Tchetchuline in 1929 [4,19–21]. They 
used the quiescent isolated lung as an oxygenator in a remarkable series of perfusion experiments, 
first with the isolated head and then using the whole body of the animal. Many workers described 
ingenious oxygenating systems for isolated organs between 1920 and 1950. Von Schroder of 
Strasburg, for instance, built the first bubble oxygenator in 1882 [11], in which air was introduced 
into a venous reservoir and the subsequent increase in pressure in the reservoir forced oxygenated 
blood into an arterial reservoir, which then perfused an isolated organ. VonEuler and Heymans [22] 
in 1932 developed the opposite and novel approach of introducing ‘atomised’ blood into an 
air⁄oxygen environment. However, there were three important devices that were to be ultimately 
developed into apparatus for clinical open heart surgery in man:the film oxygenator developed by 
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Gibbon between 1937 and 1953 [4,12,23–27]; the rotating disc oxygenator described in 1948 by 
Bjork [4,12,28]; and the improved all-glass bubble oxygenator described in 1952 by Clarke, Gollan 
and Gupta [4,29]. 
 
2.3 THE USE OF OXYGENATORS DURING THE EARLY YEARS OF OPEN-HEART 
SURGERY 
2.3.1 The Mayo-Gibbon pump-oxygenator 
The painstaking work of Gibbon in designing experimental film oxygenators that had extended over 
two decades [23–27] was crowned with success when he carried out the first successful human 
intracardiac operation under direct vision using a mechanical extracorporeal pump-oxygenator on 
18th May 1953 [4,12,24,27].Gibbon’s original objective was to develop an apparatus capable of 
suspending the natural circulation during Trendelenburg’s emergency operation for pulmonary 
artery embolectomy [23,24]. However, the first human operation was in fact closure of an atrial 
septal defect [27]. Gibbon’s early experimental oxygenator filmed blood over the inner surface of a 
rotating cylinder in an oxygen atmosphere [4,23–25]. However, this could not be enlarged to 
perfuse animals larger than a cat [30]. Thus, in Gibbon’s later animal experiments and the first 
human operation, he used a stationary screen oxygenator that he had developed [26,27]. This 
consisted of a series of six to eight wire mesh screens arranged vertically and in parallel in a plastic 
container down which the blood flowed, forming a stable film that was exposed to a flow of oxygen 
[12]. Each of the screens was 60 cm high and had a width of 10 cm. Kirklin et al. [31,32], at the 
Mayo Clinic in Rochester Minnesota, further developed the Gibbon-type stationary screen 
oxygenator into the Mayo-Gibbon pump-oxygenator apparatus after careful animal 
experimentation. This was a sophisticated commercially available unit [8]. Kirklin et al. began their 
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pioneering series of human intracardiac operations in March 1955 using the Mayo-Gibbon pump-
oxygenator and were very successful [33]. A number of cardiac surgery units worldwide obtained 
and used this apparatus [4,33,35]. The results were satisfactory but the apparatus was bulky and 
cumbersome, quite complicated to sterilise and operate, prone to the problem of blood streaming 
(resulting in diminishing blood surface area for gas exchange), and also required a large blood and 
saline priming volume [35]. 
2.3.2 The Kay-Cross disc oxygenator 
The Bjork rotating disc film oxygenator (1948) [4,28] employed in animal studies was modified for 
clinical use by Melrose in 1953, by Kay and Cross and their colleagues in 1956 [36,37], by Osborn, 
Bramson and Gerbode in 1960 [38] and by other workers. The Melrose model described in 1953 
after comprehensive animal studies was used clinically very successfully for open heart surgery for 
human patients at the Royal Postgraduate Hospital in London and other cardiac units [4,39]. It was 
an ingenious drum and disc oxygenator. It gave good service in the early days of clinical 
cardiopulmonary perfusion, but it was cumbersome and required considerable time and expertise to 
service and assemble. Later, simpler versions with Teflon
®
-coated stainless steel discs in a silicone-
coated Pyrex
®
chamber were preferred [8,12,24,36–38]. Some disc oxygenators with presterilised 
disposable plastic discs became available later [8].The need for blood conservation required the 
filming discs to be placed close to their disc enclosure. This led to risks of foaming and haemolysis 
when the discs spun, which limited their clinical applicability [24,35]. Nevertheless, rotating disk 
oxygenators continued to be favoured by many clinicians in the 1960s and 1970s despite the 
dominance of the practical disposable single use disposable bubble oxygenators until single-use 
membrane oxygenators became generally available. This was in part due to their perception that the 
Kay-Cross oxygenator caused less blood damage than the bubble oxygenator in longer surgical 
cases [12,40]. 
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2.3.3 The DeWall bubble oxygenator 
Studies of the function of the version of the bubble oxygenator devised by Clarke, Gollan and 
Gupta were important for the subsequent design of the DeWall bubble oxygenator [41] that was 
used by Lillehei and his team in their continuing pioneer work in intracardiac surgery [4,8,41–43]. 
Clarke, Gollan and Gupta [29] reported in 1950 that although small bubbles with their large surface 
area to volume ratio favoured oxygen uptake, they were less buoyant. This means that smaller 
bubbles are less likely to rise spontaneously to the surface and are more likely to remain in 
suspension – airembolism is therefore more likely. An optimum balance has therefore to be 
obtained. This optimum is believed to exist if the bubbles are between 2 mm and 7 mm in diameter 
[44]. Alternatively, a mixture of small and big bubbles may be used [43]. Furthermore, since carbon 
dioxide removal occurs by diffusion, the partial pressure of the gas vented from the oxygenator 
cannot exceed its partial pressure in blood, which is normally 4.5 kPa, in contrast to the 13.3 kPa of 
oxygen [35]; increasing the gas exchange area is of limited benefit. Carbon dioxide removal is 
therefore limited by the rate of fresh gas flow necessary to maintain an optimum carbon dioxide 
partial pressure differential.The commercially available DeWall oxygenator [12] had a vertical 
oxygenating column through which oxygen bubbled upwards at a high gas flow rate. The resulting 
foamy blood subsequently entered a defoaming chamber, in which silicone-coated surfaces 
decreased the surface tension of the bubbles, causing the smaller bubbles to coalesce into larger 
bubbles. These larger bubbles were then eliminated in a helical tubular reservoir in which the 
bubbles floated upwards while the blood was pumped downwards. In March 1954, after careful 
animal research, Lillehei and his team of the University of Minneapolis, Minnesota,began to 
conduct an interesting and relatively successful series of intracardiac operations for the closure of 
atrioventricular defects in children using the arterialblood of an adult in a controlled cross-
circulation technique [45]. Lillehei et al. then began to use the DeWall bubble oxygenator clinically 
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in May 1955 [42,46]. DeWall type bubble oxygenators gained widespread acceptance, being used in 
an estimated 90% of open heart operations worldwide in 1976 [46]. This was because of their many 
advantages: they were highly efficient because of the large cumulative surface area of the oxygen 
bubbles; they had a simple design without moving parts other than the mechanical pumps that drove 
the circulation; the components of the circuit were easily sterilized and they were disposable 
[4,8,40,47]. Their popularity was cemented with the advent of single-use, relatively inexpensive, 
presterilised and prepacked plastic versions[4,47–50]. A further advantage was that the priming 
volume required for these disposable devices was so small that a saline prime would often suffice 
without the addition of donor blood. Some bubble oxygenators were fitted with integral heat 
exchangers and had plastic venous reservoirs that allowed direct observation of the changes of 
blood volume in the circuit [35]. The DeWall oxygenator is a ‘sequential bubble oxygenator’, i.e. 
the components (bubbler, defoamer, reservoir and pump) are arranged linearly in series. Other 
variants have been designed that are ‘concentric bubble oxygenators’, in which for the sake of 
compactness the components are arranged concentrically,and also ‘foam oxygenators’, in which gas 
exchange is achieved when blood films down a column in a counter-current system [51]. Foam 
oxygenators consequently share some functional properties with both filmand bubble oxygenators. 
2.3.4 Limitations Of The Performance Of Direct Contact Extracorporeal Oxygenators 
The length of time for which either bubble or film direct contact extracorporeal oxygenators could 
be used without causing serious complications did not extend muchbeyond 4 h [8,47]. The principal 
limiting factor was damage to blood constituents due to the direct contact of blood with air surfaces 
and to contact with the plastic and metal constituents of the pump oxygenator circuit. Blood trauma 
included damage and destruction of red blood cells and platelets, coagulation disorders and protein 
denaturation. Prolonged extracorporeal perfusion could also result in vascular problems, including 
diffuse capillary leakage, poor peripheral perfusion, acidosis and progressive organ failure [52]. 
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These disadvantages of direct contact extracorporeal oxygenators could be accepted and usually 
counteracted for the relatively short duration of intracardiac surgery.Many cardiac surgery units 
used profound hypothermia, cooling the body with the aid of a heat exchanger to a nasopharyngeal, 
i.e. brain, temperature of 10–12 °C. This allowed the perfusion to be turned off completely for up to 
1 h while prolonged intracardiac surgery was performed [8,47]. Some units adopted the Drew 
method of profound hypothermia [53,54]. This technique eliminated the use of an extracorporeal 
oxygenator completely. The patient’s own lungs were employed as oxygenators during cooling by 
bypassing both the left and right sides of the heart with separate simultaneous perfusions 
[8,47,53,54]. The Mayo-Gibbon type screen oxygenators, the disposable versions of the DeWall-
type bubble oxygenator, and the Kay-Cross disc oxygenator and its modifications remained in use 
throughout the 1960s and 1970s. The disposable bubble oxygenators became very popular because 
of their convenience in use and low prime volume but there was a general view that the rotating disc 
oxygenators were somewhat better for longer cases [4,12,40,47]. There are very few papers 
attempting to make direct comparisons of the clinical performance of the various forms of direct 
contact extracorporeal oxygenators. However, in 1961 Gerbode et al. gave their reasonsfor 
marginally preferring a rotating disc over a bubble oxygenator [55]. Engell et al., writing in the 
same year, also gave their reasons for marginally preferring the disposable bubble oxygenator over 
a stationary screen oxygenator [56].The limit on the length of time that direct-contact extracorporeal 
oxygenators could be used made them unsuitable for use in the longer term for the therapeutic 
support of adults and infants suffering from respiratory distress syndrome (RDS). One thing was 
certain: clinicians concerned with cardiopulmonary perfusion in the 1950s, 1960s and 1970s 
followed the lengthy gestation of membrane oxygenators very closely, and looked forward with 
keen anticipation to the advent of a practical, disposable version. 
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2.3.5 Introduction of the membrane oxygenator 
The idea of a protective membrane between blood and air to decrease the problem of blood trauma 
inherent in direct-contact extracorporeal oxygenators began with observations by Kolff and Berk in 
1944 [57]. They noted that blood in their haemodialysis machine, which contained 20 000 cm
2
 of 
cellophane tubing, became oxygenated when exposed to aerated dialysates; the gas contents of the 
blood equilibrated with that of the dialysate through the process of passive diffusion. Although the 
potential advantage of the membrane oxygenator in decreasing the degree of blood trauma 
associated with direct-contact oxygenators was immediately evident, the problems were also 
quickly appreciated, namely: 
 a dearth of suitable membrane biomaterials, which were judged on their gas permeabilities, 
mechanical strength, how thinly they can be made without pinhole defects and blood–artificial 
surface interactions; 
 the membrane constituted an additional barrier to gas exchange; 
 the problem of optimal distribution of blood and gas flows so that there is efficient gas exchange. 
The emphasis in early membrane oxygenator development concentrated on finding suitable 
biomaterials [58], as early biomaterials had low gas exchange performance and poor mechanical 
properties, limiting the developmentof membrane oxygenators. Of the earliest available materials, 
ethylcellulose and polyethylene were the most permeable to oxygen and carbon dioxide [59]. 
Polyethylene offered good mechanical strength and was rolled into a coil for the first experimental 
membrane oxygenator [60,61]. Clowes, Hopkins and Neville in 1958 used25 m
2
 of the more 
permeable ethylcellulose [62] (soon replaced by the mechanically stronger polytetrafluoroethylene 
or Teflon
®
 [63]) in multiple sandwiched layers in their device that constituted the first clinical 
membrane oxygenator. Membrane support with grooved plates was later added, making an 
arrangement akin to a manifold of straight capillaries in parallel. This was to stop blood collecting 
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unpredictably in thick rivulets, a problem similar to that of blood streaming in film oxygenators. 
One disadvantage of hydrophilic membrane oxygenators is their tendency to leak plasma in a 
manner akin to tents leaking water when wetted on the inside. This severely shortened the duration 
of the use of the membrane lung. To prevent this, membranes made of hydrophobic polymers [58] 
were used. These materials were initially derived from packaging materials used inthe capacitor 
industry, such as polytetrafluoroethylene (Teflon
®
). With hydrophobic membranes, Melrose [64] 
realised in 1958 that it is carbon dioxide removal that was the limitation, as carbon dioxide 
solubility inhydrophobic solids is much less than its solubility inhydrophilic solids. To emphasise 
the importance of carbon dioxide transfer, the term ‘membrane lung’ was coined. This problem was 
partly solved by the use of silicone as the hydrophobic material in membrane lungs. Although 
silicone had been discovered in 1947 and had played an important role as a defoaming agent in 
direct contact devices, its excellent gas exchange properties [65] were not discovered until 1957. 
Silicone had a permeability (the product of diffusivity and solubility) for oxygen from four to five 
times higher than this for carbon dioxide, these figures being some 40 times higher than those for 
Teflon
®
. Early silicone membranes had a number of problems. They had low mechanical strength 
and were not free of pinholes when made into a thin film. Solutions were found to these problems. 
In 1959, Thomas designed the first silicone membrane lung using a thin continuous silicone 
membrane on a fabric support, which was made by dip-coating a nylon mesh, and the pairing of two 
sheets of ultrathin membranes together so as to decrease the risk of leakages through random 
pinhole defects. The definitive solution belonged to Burns [66] who, in1959, developed a new 
process at Hammersmith Hospital in London for the low-cost production of thin films of silicone 
membranes that were virtually free of pinholes and had greatly increased strength. Modern versions 
of the silicone membrane oxygenators are still in use and are marketed as long-term extracorporeal 
oxygenators [67]. 
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2.3.6 Improving the gas exchange efficiency of membrane oxygenators 
With sufficiently thin membranes, the gas exchange bottleneck was now recognised as having 
shifted from the membrane to gas diffusion through blood. This was a result of the thickness of the 
blood layer. Marx et al. [68] determined that oxygen transfer into a blood film is proportional to the 
square of the thickness of the blood film and the diffusion resistance of the boundary layer. This 
latter factor requires elaboration. In alveolar capillaries, the blood channels are one cell thick, 
resulting in efficient gas exchange. In artificial oxygenators, the blood channels are much thicker. 
With laminar flow, blood flows in orderly layers through these channels. The boundary layer, i.e. 
the layer that is adjacent to the gas exchange surface, quickly equilibrates with the venting gas. 
However, this equilibration is slow to spread through the other layers because of the low diffusivity 
of gas through blood, with consequent deterioration of gas exchange efficiency. Subsequent 
development therefore concentrated on minimising these two bottlenecks. The first silicone 
capillary oxygenator, comprising capillaries that were 100–500 µm in diameter, was designed by 
Bodell et al.[69] in 1963. The small diameter of the hollow fibres decreases the distance of the 
blood layers from the gas exchange surface in two dimensions. Capillary oxygenators also have the 
additional advantage of being better able to control the volumes of both gas and blood 
compartments. Configurations with blood inside the fibres and oxygen outside and the reverse 
configuration of blood outside the fibres and oxygen inside were tried. Wilsonet al. [70] showed 
that the preferred configuration used blood flowing inside the fibres. However, the opposite is the 
case with current microporous hollow-fibreoxygenators, as is described later. The second problem, 
i.e. the diffusion resistance of the boundary layer, was addressed by the induction of secondary 
flows in blood. Secondary flows are fluid flows that are additional to the mainstream. They may be 
used to disrupt laminar flow and impart convective mass transfer to the mass of the fluid. Mixing 
and therefore gas exchange performance are thus increased. Passive internal secondary flows are 
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induced by forcing blood to ‘eddy’ around passive obstacles, e.g. forcing blood to move in curved 
paths around a helically wound tube [71] or by the insertion of surface elements into blood passages 
[72]. Active secondary flows are induced by using energetic mechanisms to disrupt laminar flow 
more effectively, resulting in greater gas exchange efficiency. Mechanisms devisedfor this include: 
 periodic deformation of the membrane through cyclical oxygen pressure to produce microscopic 
foci of mixing [73]; 
 a rocking membrane envelope [74]; 
 pneumatic pulsation of the membrane [74]; 
 arotating membrane-bound disk [74]; 
 moving rod massage [75]; 
 the toroidal membrane oxygenator [76,77]; 
 the annular membrane oxygenator by Gaylor et al. [78]; 
 vortex-shedding designs [79,80]. 
The measures employed were very successful in enhancing gas mass transfer. Kolobow’s device 
[73] infact exceeded 200 ml oxygen.min
-1
.m
2
, the limit for the thickness of the silicone membrane 
used. This was because the membrane inverted and stretched into the gas side, increasing the 
surface area when hypobaric pressure was applied. Kolobow’s device was mass-manufactured and 
marketed by SciMed, then AveCor and now MedTronic, becoming the only solid silicone 
membrane device consistently available for long-term life support during the past few decades [81]. 
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2.4 ECMO MODALITIES 
ECMO is an invasive technique where blood is drained from the venous system, pumped through 
an oxygenator, and then re-infused to the patient [82]. There are two basic types of ECMO support: 
venovenous (VV) ECMO provides only respiratory support, whilst venoarterial (VA) ECMO 
bypasses both the heart and lungs and is thus the appropriate type of ECMO for patients with 
circulatory failure.  
2.4.1 VV ECMO 
VV ECMO is the preferred route to provide either complete or partial support of the lungs in the 
management of severe respiratory failure when cardiac output is sufficient [83]. However, cardiac 
function is often improved with VV ECMO because mechanicalventilation is concurrently reduced 
and oxygen supply to the heart is ameliorated. With VV ECMO, both drainage and return cannula 
are placed in systemic venous system. The cannulation site depends on patient size [84]. In older 
children and adults, the drainage of the oxygen-poor blood is from femoral vessels, and the 
reinfusion of oxygen-rich blood is through the right internal jugular vein [85] (Figure 1).  
 
Figure 1: Abrams et al. 
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VV ECMO can also be delivered using a single double-lumen cannula inserted through the internal 
jugular vein into the right atrium, although cannula size constraints have previously restricted this 
technique to infants [86] (Figure 2). 
 
Figure 2: Abrams et al. 
 
One hundred percent oxygenated blood from the ECMO return cannula mixes with systemic venous 
blood, which than traverses the pulmonary system. Theoretically, only oxygen-depleted systemic 
venous blood enters the ECMO drainage cannula. However, depending on the positions of the 
inserted cannula, a variable proportion of oxygenated blood from the return cannula enters the 
drainage cannula, known as recirculation. Mixed venous oxygen saturation (SvO2) is determined by 
the relative contributions of the ECMO return cannula (oxygenated blood) to pulmonary blood flow 
and the systemic venous return (deoxygenated blood). Recirculation reduces the delivery of 
oxygenated blood to the pulmonary artery, and thus reduces the SvO2. SaO2 is determined by 
ECMO flow, patient’s systemic venous return, the degree of recirculation, the SvO2 venous blood 
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and pulmonary function. Of these parameters, ECMO circuit flow is the most important and easily 
manipulated determinant of SaO2 in the absence of significant recirculation [87]. 
2.4.2 ECMO for Respiratory Failure 
Acute respiratory distress syndrome.The most extensively studied respiratory indication for ECMO 
is acute respiratory distress syndrome (ARDS) [88]. In circumstances in which invasive mechanical 
ventilation is necessary to support gas exchange, positive-pressure ventilation may potentiate lung 
injury [89]. The only ventilation strategy proved to reduce mortality in ARDS is a volume and 
pressure-limited ventilation strategy [90]. ECMO has he potential to improve outcomes in patients 
with ARDS by providing adequate oxygenation while facilitating lung protective ventilation by 
correcting unsustainable levels of hypercapnia and respiratory acidosis that may accompany low–
tidal volume ventilation [91]. Potential indications for ECMO in the setting of ARDS have been 
proposed [88]. 
Early randomized trials were unsuccessful in demonstrating a survival benefit from ECMO in 
patients with severe forms of ARDS. More recently, the impact of modern extracorporeal support 
on survival in patients with severe ARDS was evaluated in the Conventional Ventilation or ECMO 
for Severe Adult Respiratory Failure trial, in which 180 subjects with severe, potentially reversible 
respiratory failure were randomized to conventional mechanical ventilation or referral to a 
specialized center for consideration of ECMO (92). Compared with the conventionally managed 
group, those referred for consideration of ECMO had a significantly lower rate of death or severe 
disability at 6 months (37% vs. 53%; relative risk: 0.69; p = 0.03).  
Other nonrandomized observational studies, particularly during the influenza A (H1N1) pandemic 
in 2009, have shown conflicting results of the impact of ECMO on survival in severe ARDS [93].  
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Hypercapnic respiratory failure. With an improved risk benefit ratio, there is great potential to use 
ECCO2R to manage hypercapnic respiratory failure, thereby minimizing or even eliminating the 
need for a ventilator. In chronic obstructive pulmonary disease, invasive mechanical ventilation is 
associated with multiple complications, including dynamic hyperinflation and elevations in intrinsic 
positive end-expiratory pressure, ventilator-associated pneumonia, and impaired delivery of 
aerosolized medications [94,95]. Several small case series have demonstrated the feasibility of 
avoidance of or rapid weaning from invasive mechanical ventilation, with ECCO2R used to manage 
gas exchange [96–98]. With correction of hypercapnia and respiratory acidosis, dyspnea and work 
of breathing rapidly improve, facilitating early mobilization [98]. Although early mobilization has 
been described with invasive mechanical ventilation [99], it is more likely to be successful with the 
substitution of ECCO2R for mechanical ventilation because of the significant improvement in 
dyspnea that is seen with ECCO2R compared with mechanical ventilation in the hypercapnic 
population [98]. The risks of ECCO2R must be weighed against the benefit of minimizing invasive 
mechanical ventilation, and additional studies are required to define the ideal patient population and 
the economic impact of such a strategy before it can be recommended for clinical use. Similarly, 
ECCO2R may be considered in other forms of hypercapnic respiratory failure, including refractory 
status asthmaticus, in which the ability to avoid invasive mechanical ventilation altogether is 
potentially advantageous (100,101). 
Bridge to lung transplantation and post-transplantation primary graft dysfunction. Although 
ECMO has traditionally been considered a relative contraindication to lung transplantation because 
of poor perioperative outcomes [102], more recent studies have reported excellent post 
transplantation survival, especially at centers with more extensive experience [103,104]. With the 
potential for ECMO to provide sufficient gas exchange to supplant the ventilator, a nonintubated 
ECMO strategy may be considered for some transplantation candidates who would otherwise be 
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ventilator dependent, a population with poor outcomes related to ventilator-associated 
complications [105]. Outcomes may be further optimized when such a strategy is combined with 
active physical therapy and should be considered in patients who would otherwise be inactivated 
from the transplantation list because of deconditioning. This is particularly true for those patients in 
whom ECMO or ECCO2R alleviates dyspnea sufficiently to permit rehabilitation [104,106,107]. A 
major limitation to the use of ECMO for end-stage respiratory failure is the lack of a destination 
device therapy, with ECMO remaining an intervention for which an intensive care unit is required. 
In severe cases of primary graft dysfunction, a form of acute lung injury that is the leading cause of 
early death after lung transplantation [108], ECMO may be used to support gas exchange while the 
allograft recovers. Studies have described similar survival in cases of ECMO-supported severe 
primary graft dysfunction compared with those with less severe primary graft dysfunction without 
ECMO support, particularly when instituted early [109]. However, ECMO has not been shown to 
affect long-term allograft function. 
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2.4.3 VA ECMO 
VA ECMO is essentially a modification of the cardiopulmonary bypass circuit which is used 
routinely in cardiac surgery. In VA ECMO, oxygen-depleted blood drains into the circuit from 
venous system and oxygenated blood is pumped back into the systemic side, which both augments 
gas exchange and supports cardiac function. Cannulation for VA ECMO can be established 
centrally or peripherally. With central cannulation (Figure 3), blood is drained directly from the 
right atrium and return to the proximal of ascending aorta.  
 
Figure 3: Marasco et al. 
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Figure 4: Marasco et al. 
 
With peripheral cannulation (Figure 4), blood is drained from the proximal great veins (via a 
femoralor jugular vein) using a surgically cut-down or modified Seldinger technique, and returned 
to the aorta via cannulation of a carotid, axillary or femoral artery (Figure 5). 
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Figure 5: Abrams et al. 
 
 Systemic arterial blood flow is the total of the ECMO circuit flow and any ejection from the left 
ventricle. Systemic blood pressure is determined by total arterial blood flow and the vascular tone. 
When left ventricle (LV) cannot contribute to the systemic arterial blood flow, the patient’s 
systemic arterial oxygen saturation (SaO2) is determined entirely by the oxygen saturation of blood 
in the ECMO return cannula, which is 100%. However, if there is a contribution from the LV, SaO2 
depends on the relative flow and oxygen saturation of blood from both the ECMO circuit and blood 
ejected by LV. This detail becomes important if you place the ECMO return cannula via femoral 
artery in a patient suffering from a severely compromised lung function. In this condition, coronary 
arteries, cerebral blood vessels and upper limbs are under threat of hypoxaemia because proximal 
branches of the aorta receive predominantly deoxygenated blood ejected from the left heart. Even 
though there is a presence of sufficient LV function, this situation persists as long as pulmonary 
function is good or the return cannula is placed centrally [87]. 
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ECMO remains a short-term support device, essentially the circuit is smaller than a standard 
cardiopulmonary bypass circuit, transportable and closed to the atmosphere. The cannulae are also 
specifically designed for ECMO. The duration of support with ECMO has greatly increased with 
improving oxygenators and medical management,and whereas support was previously in the order 
of days, patients can now be maintained on ECMO for weeks. In most patients the duration of 
support required is approximately1 week. Most commonly, it is instituted in an emergency or urgent 
situation after failure of other treatment modalities. 
2.4.4 ECMO for Cardiac Failure 
In terms of cardiac failure, the most common indications for ECMO are post-cardiotomy (that is 
unable to get the patient off cardiopulmonary bypass following cardiac surgery) [110], post-heart 
transplant (usually due to primary graft failure) [111] and severe cardiac failure due to almost any 
other cause (e.g. decompensated cardiomyopathy, myocarditis, acute coronary syndrome with 
cardiogenic shock, profound cardiac depression due to drug overdose or sepsis).  
In making the decision to institute ECMO, several considerations must be weighed. Most 
importantly, one must consider the likelihood of organ recovery. If the organ failure is thought to be 
reversible with therapy and rest on ECMO, then institution of this mechanical support is 
appropriate. If recovery is thought not to be a possibility in that particular patient, then other factors 
must be taken into account. With regards to cardiac failure, if recovery is not expected, what other 
options are there available for this patient? Consideration must be given to the patient’s eligibility 
for transplantation, other mechanical assist devices to bridge the patient to transplant or whether it is 
appropriate for a definitive mechanical assist device to be inserted as destination therapy. Obviously 
implantation of ECMO in an 80 year old with no hope of native organ recovery is a futile exercise 
as there is no endpoint for this patient’s treatment. Such implementation of ECMO could be seen as 
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unethical in that it puts a patient (and their family) through a futile exercise, falsely raises their 
hopes, utilizes resources better used on someone with achance of survival and blocks an intensive 
care bed. Other contraindications to the institution of ECMO include disseminated malignancy, 
advanced age, graft vs.host disease, known severe brain injury, unwitnessed cardiac arrest or 
cardiac arrest of prolonged duration. There may be other technical contraindications to consider 
such as aortic dissection or aortic incompetence (discussed below). 
If ECMO has been instituted for cardiac support, thereare several other end points to their recovery 
pathway. ECMO can either be weaned if the heart has recovered, a more permanent mechanical 
device can be inserted orthe patient may receive a heart transplant. The more permanent mechanical 
devices which can be implanted allow the patient to ambulate, rehabilitate, and be discharged home 
with the device. The aim then is to either wait for further cardiac recovery to allow explant of the 
device or to list the patient for transplantation. Patients can be supported by a VAD (Ventricular 
Assist Device) at home for months or even a year prior to receiving a heart transplant. More 
recently, fully implantable mechanical assist devices are being used as destination therapy. 
Destination therapy is considered in patients who have end stage heart failure which has not 
responded to any other form of treatment, and who are not suitable for transplantation. This is 
usually due to advanced age (>65) or other comorbidities. Several technical considerations need to 
be taken into account also before instituting ECMO. Aortic incompetence is a relative 
contraindication, particularly if severe. In such situations consideration of aortic valve replacement 
would need to be made. Lesser degrees of aortic incompetence may be managed with a left 
ventricular vent. Failure to insert a vent leads to ventricular distension, compromised 
subendocardial blood flow and would impact on recovery and the ability to wean ECMO. 
Post-operative cardiogenic shock and post-transplant primary graft failure. Post-cardiotomy 
cardiogenic shock is an uncommon but highly lethal complication of cardiac surgery. ECMO may 
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be considered as temporary support post-operatively, particularly when unable to wean from 
cardiopulmonary bypass in the operating room [112]. Mortality in patients requiring this level of 
support remains high [113]. Primary graft failure (PGF) is a well-recognized complication of heart 
transplantation associated with a high mortality, for which ECMO has been used as temporary 
support [114,115]. As expected, overall survival for patients with PGF requiring ECMO is worse 
than in those who do not develop PGF. However, patients with ECMO-supported PGF who survive 
beyond the early post-transplantation period have comparable long-term survival with non-PGF 
transplant recipients [115,116]. 
Cardiogenic shock complicating acute myocardial infarction. There are no randomized controlled 
trials comparing ECMO with other mechanical support systems in myocardial infarction–associated 
cardiogenic shock, but several nonrandomized studies suggest a survival advantage from the early 
use of ECMO in such circumstances (117,118). In an observational study of patients with ST-
segment elevation myocardial infarction–related cardiogenic shock undergoing percutaneous 
coronary intervention (PCI) with and without ECMO support, those receiving ECMO had 
significantly lower 30-day mortality (39.1% vs. 72%;p = 0.008) (54). Interpretation of these data is 
limited by the fact that cohorts were enrolled over different time frames (1993 to 2002 for the non-
ECMO cohort vs. 2002 to 2009 for the ECMO cohort), potentially leading to discrepancies in 
treatment between groups, especially given that coronary stents were unavailable at the study center 
before 1998. Higher rates of Thrombolysis In Myocardial Infarction flowgrade 3 achieved in the 
ECMO group may reflect improved hemodynamic stability in the catheterization laboratory or, 
alternatively, may be a consequence of improved PCI technique over time. Ultimately, randomized 
controlled trials are needed to determine the true benefit, if any, of ECMO in myocardial infarction–
associated cardiogenic shock. 
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Fulminant myocarditis. ECMO use has been investigated as a modality to support non ischemic 
cardiogenic shock, including fulminant myocarditis [119-122]. Patients with fulminant myocarditis 
who are successfully bridged with ECMO to recovery may have long-term prognoses comparable 
with those of hemodynamically stable patients with acute myocarditis [119]. In 1 cohort of patients 
who received either a biventricular assist device (n = 6) or ECMO (n = 35) for fulminant 
myocarditis with refractory cardiogenic shock, overall intensive care unit survival was 68%, with 
higher severity of illness and elevated cardiac biomarkers serving as independent predictors of 
mortality and an inability to wean from ECMO (121). ECMO may be as efficacious as a ventricular 
assist device (VAD) while having the advantage of being less invasive. In a study comparing 
ECMO with biventricular assist devices for fulminant myocarditis, those receiving ECMO had 
comparable rates of weaning from device therapy and survival to hospital discharge without the 
need for transplantation (83% vs. 80%) and more rapid improvement in renal and hepatic laboratory 
profiles, despite having a higher severity of illness and worse left ventricular function before device 
implantation [122]. 
Sepsis-associated cardiomyopathy. Myocardial depression is a well-recognized consequence of 
severe septic shock [123]. There are emerging data suggesting that ECMO may have a role in 
supporting patients who develop refractory cardiac failure in this setting [124,125]. Larger studies 
are needed to determine whether the benefit of ECMO outweighs the risk, especially in cases in 
which septic shock is complicated by marked disturbances in coagulation. 
Pulmonary hypertension. ECMO is an emerging management option in patients with 
decompensated pulmonary hypertension with concomitant right ventricular failure, particularly 
when there is an acutely reversible process, medical management has not been optimized, or lung 
transplantation is a consideration [126]. ECMO for this indication typically requires a femoral 
venoarterial configuration to bypass the high resistance of the pulmonary vasculature and 
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decompress the right ventricle. However, 3 configurations have been used to avoid femoral 
cannulation. Internal jugular venous drainage may be combined with subclavian arterial reinfusion. 
In patients with pre-existing intra-atrial defects, a dual-lumen cannula maybe oriented with the 
reinfusion jet directed across the defect (rather than across the tricuspid valve), effectively 
providing an oxygenated right-to-left shunt while decompressing the right ventricle [127,128]. 
Additionally, arteriovenous ECMO can be inserted between the main pulmonary artery and the left 
atrium, though this typically requires a sternotomy [129]. When ECMO is initiated as a bridge to 
recovery, pulmonary vasodilators may be optimized while the underlying acute process is treated 
[126]. When the goal of ECMO is to bridge to transplantation, pulmonary vasodilators may be 
down-titrated to preferentially shunt blood through the extracorporeal circuit and away from the 
high-resistance pulmonary vasculature, thereby optimizing systemic oxygenation [130]. Reducing 
the dosage of intravenous pulmonary vasodilators will also minimize the degree of systemic 
vasodilation that may occur as the medications pass through the ECMO circuit and into the arterial 
circulation. 
Pulmonary embolism. Massive pulmonary embolism may likewise benefit from ECMO. A 
retrospective single-center review of ECMO for massive pulmonary embolism, including patients in 
active cardiac arrest, demonstrated 62% overall survival when combined with anticoagulation or 
surgical embolectomy [131]. The combination of ECMO, thrombolysis, and catheter-directed 
thrombectomy or embolus fragmentation has also been reported, with 30-day survival of 70% 
[132].  
Extracorporeal cardiopulmonary resuscitation. “Extracorporeal cardiopulmonary resuscitation” 
(ECPR) is the term used to describe the institution of extracorporeal support to restore circulation 
during cardiac arrest. Although there are no randomized controlled trials investigating the efficacy 
of ECPR for cardiac arrest, its use has been steadily increasing [133–136). In a prospective, 
63 
 
observational study of witnessed in-hospital cardiac arrests, propensity analysis matching 46 
subjects who received conventional cardiopulmonary resuscitation (CPR) with 46 subjects who 
received ECPR demonstrated significantly higher survival at discharge in the ECPR group (32.6% 
vs. 17.4%; p < 0.0001) and at 1 year (hazard ratio: 0.53; p = 0.006) (69), with a trend toward 
improved neurological outcomes. In multivariate analysis, an initial rhythm of ventricular 
fibrillation or ventricular tachycardia and use of ECPR were positively associated with survival to 
discharge. A more recent propensity analysis of patients who experienced in-hospital cardiac arrest 
demonstrated significantly higher 2-year survival with minimal neurological impairment in those 
treated with ECPR compared with conventional CPR (20% vs. 5% p = 0.002). Independent 
predictors associated with minimal neurological impairment included age <65 years, CPR duration 
<35 min, and subsequent cardiovascular intervention [135]. Regarding out-of-hospital cardiac 
arrests, a recent matched propensity analysis demonstrated significantly higher neurologically intact 
survival at 3 months in those who received ECPR compared with conventional CPR (29.2% vs. 
8.3%; p = 0.018) (72).With the ability of ECMO to both maintain systemic circulation during 
cardiac arrest and increase coronary perfusion pressure, the combination of ECPR and intra-arrest 
PCI may greatly improve the likelihood of successful defibrillation and recovery in cardiac arrest 
due to an acute coronary syndrome. A multicenter nonrandomized study demonstrated the 
feasibility of combining ECMO and emergency coronary angiography in 81 subjects, 61 of whom 
received intra-arrest PCI [137]. Compared with those who received ECMO and coronary 
angiography without PCI, those receiving PCI achieved higher rates of resumption of spontaneous 
beating (100% vs. 60%; p < 0.001), weaning from ECMO (59% vs. 28%; p = 0.009), 30-day 
survival (36% vs. 12%; p = 0.03), and favorable neurological outcomes(33% vs. 4%; p = 0.005). In-
hospital (vs. out-of-hospital) cardiac arrest and shorter duration from collapse to initiation of ECMO 
were correlated with 30-day survival. Although observational trials suggest a possible survival 
advantage of ECPR over conventional CPR, overall survival remains relatively low. More research 
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is needed to define the patient population that would derive the greatest benefit from extracorporeal 
resuscitation, with an emphasis on survival with minimal neurological impairment. The 2010 
American Heart Association guidelines for cardiopulmonary resuscitation and emergency 
cardiovascular care do not recommend the routine use of ECPR for cardiac arrest. However, ECPR 
may be considered when the time without spontaneous circulation is short, resuscitation attempts 
are adequate, and the cause of cardiac arrest is potentially reversible [138]. The guidelines 
emphasize that ECPR use should be restricted to centers at which it is readily available and that its 
initiation and management require highly trained personnel and specialized equipment. 
Bridge to VAD implantation or heart transplantation. VADs may be used as a bridging therapy to 
heart transplantationin appropriately selected patients with severe cardiac dysfunction [139], with 
the advantage of being able to function as destination devices if transplantation is not feasible. 
ECMO has also been reported as a bridging therapy to heart transplantation or VAD implantation or 
as a bridge to decision when prognosis is uncertain [140–142]. However,the duration of support that 
can be provided is shorter than for VADs, making transplantation or transition to VAD of greater 
urgency, and patients receiving ECMO support must remain within an intensive care unit [142]. 
Success of ECMO bridging varies greatly and depends in large part on pre-ECMO patient 
characteristics and organ availability in the cases in which transplantation is the goal. In a 
retrospective review of 70 patients in whom ECMO was used as a bridgeto heart transplantation, 31 
(44%) were bridged to either heart transplantation (n = 15) or VAD implantation (n = 16), though 
only 11 (73%) and 8 (50%) of the heart transplantand VAD recipients, respectively, survived to 
hospital discharge, highlighting the limitations of bridging therapy in this highly morbid patient 
population [140]. Age > 50 years, CPR before ECMO initiation, and high sequential organ failure 
assessment score were independent predictors of unsuccessful bridging. Pre-implantation CPR as a 
predictor of poor outcomes was corroborated in a more recent single-center study of 90 patients 
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who received mechanical circulatory support (VAD or ECMO) for refractory cardiogenic shock 
[143]. Forty-nine percent received short-term VAD support as a bridge to decision, and 51% 
received ECMO when neurological status was uncertain or there was complete hemodynamic 
collapse or severe coagulopathy. Overall survival was 49%, with 26% of patients transitioned to 
implantable VADs, 18% recovering sufficient native cardiac function, and 11% bridged to 
transplantation. CPR at the time of implantation was an independent predictor of in-hospital 
mortality (odds ratio: 5.79; p = 0.022). These studies highlight the need for careful consideration of 
relative and absolute contraindications to mechanical circulatory support. In particular, ECMO for 
cardiogenic shock superimposed on chronic cardiomyopathymay be associated with particularly 
poor outcomes [144].  
ECMO to prevent acute right ventricular failure after LVAD implantation. Both femoral 
venoarterial ECMO and percutaneous venous-to-pulmonary arterial ECMO have been successfully 
used to provide right ventricular support in patients with biventricular dysfunction undergoing 
LVAD implantation [145,146]. In this setting, ECMO can allow time for the already compromised 
right ventricle to get accustomed to the increasing preload,thereby avoiding distension and right 
ventricular failure leading to poor filling of the LVAD. 
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2.5 ECMO CIRCUITS AND EQUIPMENT 
Basically, an ECMO circuit consists of the drainage and return cannulae, tubing, a driving force 
(pump) and a gas/heat exchanger. Apart from differences in the cannulae, similar circuits are used 
for VV and VA ECMO. 
2.5.1 Pump 
Most ECMO circuits use two-types of pumps: roller and centrifugal. The literature is inconsistent 
with regard to biocompatibility and complication rates comparing these two pump principles, with a 
slight tendency in favour of the roller pump [146–148]. Centrifugal pumps consist of a vaned 
impeller or nested, smooth plastic cones, which when rotated rapidly up to 3000 revolutions/min, 
propel blood by centrifugal force [149]. Centrifugal blood pumps generate up to 900 mmHg of 
forward pressure, but only 400–500 mmHg of negative pressure, and therefore less cavitation and 
fewer gaseous microemboli. Blood flow is preload and afterload dependent. Thus, there is no fixed 
relationship between pump speed and blood flow, necessitating the presence of a flowmeter within 
the circuit. They can pump small amounts of air, but become “deprimed” if more than 30–50 ml of 
air enters the blood chamber. If hypovolaemia occurs, the inlet pressure becomes more negative and 
pump speed remains constant, however the blood flow rate is decreased. During VA ECMO, a 
change in systemic vascular resistance changes the relationship between the circuit flow and the 
speed of the pump. Similarly, pump failure during VA ECMO can result in a reverse of the flow in 
the circuit [87]. Roller pumps consist of a length of 1/4- to 5/8-inch (internal diameter) tubing, 
which is compressed by two rollers 180° apart inside a curved raceway. Rollers mounted on a 
rotating arm progressively compress a segment of tubing pushing blood ahead of the roller and flow 
rate depends on the diameter of the tubing rate of rotation, the length of the compression raceway, 
and completeness of compression. A roller pump is usually used in conjunction with a blood-filled 
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bladder sited between the drainage cannula and the pump to allow continuous pumping despite the 
alterations in the patient’s intravascular effective volume. If hypovolaemia occurs, pump speed and 
therefore blood flow decrease. Roller pumps are afterload independent. During VA ECMO, a 
significant change in systemic vascular resistance does not influence blood pumping. Since the 
driving force of drainage into the bladder is gravity, roller pumps have to be kept below the level of 
patient, which becomes crucial when transporting patients on ECMO. With roller pumps, there is a 
direct relationship between pump rate and blood flow; thus, a flowmeter is not required. Roller 
pumps are cheaper, reliable, safe and have small priming volumes, but can produce high negative 
pressures and micro-particles shed from compressed tubing (spallation)[150]. Roller pumps are 
vulnerable to careless operation,back-flow when not in use if rollers are not sufficiently occlusive, 
excessive pressure with rupture of connections if the return tubing becomes obstructed, tears in 
tubing, and changing roller compression settings during the operation. Roller pumps, but not 
centrifugal pumps, are used for sucker systems and for delivering cardioplegic solutions. 
Centrifugal pumps produce pulseless blood flow and standard roller pumps produce a sine wave 
pulse around 5 mmHg. The return tubing cannula dampens the pulse of pulsatile pumps, and is 
difficult to generate pulse-pressures above 20 mmHg within the body during full CPB [151]. 
The two principles can so far be looked at as being more or less equivalent, even for long-term 
extracorporeal support. Some centres use two pumps in parallel, thus backing up their unit in case 
of pump or oxygenator malfunction. 
A nonocclusive pump avoids stress to blood components while abolishing negative pressures acting 
on the drained blood. However, in relation to the pump rate and the patient’s intravascular volume, 
various amounts of blood might be pumped at a time. Using a servo-controlled mechanism is 
another way to prevent excessive negative pressure. Servo-controlled pumping allows setting of a 
calculated maximum negative pressure and slows down the rate of the pump when you are close to 
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the limit [86]. An exciting development was the discovery of intubing pumps which are the 
miniaturised forms of high-end pumps that are able to pump blood flows between 0 and 10 L/min. 
These pumps require very small amounts of priming volumes and can be integrated at any location 
of the ECMO. Inline pumps can support arteriovenous circuits at any time,drive VV orVA circuits; 
and can be placed at the bedside.  
2.5.2 Oxygenators 
Membrane oxygenators mimic the human lung by interspersing a thin membrane of either 
microporous polypropylene hollow fibre (0.3- to 0.8-μm pores) or non-microporous silicone rubber 
between the gas and blood phases. Membrane oxygenators are safer than bubble oxygenators 
because they produce less particulate and gaseous microemboli, are less reactive to blood elements, 
and allow superior control of blood gases [152]. Considering microporous membrane oxygenators, 
while preventing gas from entering blood, plasma-filled pores also facilitate transfer of both oxygen 
and carbon dioxide. In order to obtain a sufficient amount of oxygen, blood has to be spread as a 
thin film over a large area with high differential gas pressures because oxygen is poorly diffusible in 
plasma whereas carbon dioxide is highly diffusible in plasma so it can easily be removed from the 
blood. Areas of turbulence and secondary flow increase diffusion of oxygen within blood. 
Considering non-microporous membrane oxygenators, O2 and CO2 diffuse across thin silicone 
membranes, which are made into envelopes and wound around a spool to produce a spiral coil 
oxygenator. Gas passes through the envelope and blood passes between the coil windings. 
Polypropylene hollow-fibre oxygenators are the standard oxygenators used during CPB. Their 
priming volumes are small, gas-transfer rates are high and resistance is low so they are at least 
theoretically superior to silicone membrane oxygenators [153]. However, in the past series, it was 
discovered that over time, the micropores become permeable to fluid causing plasma to leak into the 
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gas phase and out the exhalation port resulting in deteriorating gas exchange and developing 
coagulopathy. Because of protein leakage that deteriorates membrane function, these spiral coil 
oxygenators are preferred over hollow fibre microporous oxygenators for the prolonged perfusions 
(>2–3 days) [154]. 
Peek et al. compared silicone membrane oxygenators with polypropylene hollow-fibre oxygenators 
and concluded that, silicone oxygenators have excellent biocompatibility and durability but provide 
less efficient gas exchange, are bulky, are difficult to prime and have high resistance to blood flow 
[155]. 
In 2002, Wiesenack et al. tested a new membrane oxygenator featuring a very thin (0.05μm), solid 
membrane on the blood side of a highly porous support matrix. This membrane reduced the risk of 
gas emboli and plasma leakage during prolonged CPB, but impaired transfer of volatile anaesthetics 
[156]. 
Haworth directed the oxygenator development to the construction of smaller devices with low-
priming volumes, high gas transfer rates, and a lower resistance against the streaming blood [153]. 
Another very interesting development was the introduction of small silicone rubber hollow fibre 
oxygenators by Motomura et al., reaching gas transfer rates very similar to those of conventional 
hollow fibre oxygenators [157]. 
In the early 2000s, a new generation of oxygenator was introduced into clinical practice, containing 
non-microporous hollow fibres constructed of polymethylpentene (PMP). PMP oxygenators 
combine the durability of silicone membranes with the ease of use and efficient gas exchange of 
hollow-fibre construction. In 2005, Khoshbin et al. [155], suggested that, compared with silicone 
membrane oxygenators, PMP oxygenators are associated with reduced red cell and platelet 
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transfusion and improved gas change. Compared with polypropylene hollow-fibre oxygenators, 
PMP oxygenators have improved durability and reduced requirement for blood product transfusion. 
2.5.3 Cannulae and Tubing 
The tip of the drainage cannula is usually the narrowest part of the perfusion system and 
inappropriate catheters can produce high pressure differentials and turbulence. To put it simply, the 
larger the diameter of the cannula, the better the flow. Usually for the adult patients, the drainage 
cannula should be 23F to 25F, and the return cannula should be 17F to 21F. The various 
components of the heart–lung machine are connected by polyvinyl tubing and fluted polycarbonate 
connectors. Medical grade polyvinyl chloride tubing is universally used because it’s flexible, 
compatible with blood, inert, nontoxic, smooth, transparent, and resistant to kinking and collapse, 
and can be heat sterilised. Bioactive coating of artificial surfaces to decrease the necessity of 
systemic anticoagulation is another issue that has an important effect on the rate of complications 
during ECMO procedures [159]. Heparin can be attached to blood surfaces of all components of the 
extracorporeal circuit by ionic or covalent bonds. There are many reports that have studied the use 
of heparin-coated circuits but the effectiveness of them remains controversial because studies are 
contaminated by patient selection, reduced doses of systemic heparin, and washing or discarding 
field-aspirated blood [160]. Little is known about the use of heparin-coated ECMO units in patients 
with heparin/platelet factor4 (HPF 4) antibodies, very probably responsible for the development of 
heparin induced thrombocytopaenia type II (HIT II) [86]. Koster et al., suggested that heparin 
immobilised on artificial surfaces neither induces HPF 4 antibody formation nor supports its 
persistence [161]. On the contrary, Cruz et al. pointed out a relation between HIT II development 
and thromboembolic complications in patients with heparin-coated cardiac stents [162]. In general, 
heparin as a substance acting late in the coagulation cascade seems not to be the ideal drug to be 
used for the purpose of biocompatibility. 
71 
 
Direct contact between blood and the ECMO circuit leads to activation of inflammatory mediators, 
particularly the complement activation pathway [163]. Although a majority of studies indicate that 
heparin coatings reduce concentrations of C3a and C5b-9 [164,165], the inflammatory response to 
extracorporeal circulation is not reduced and the evidence for clinical benefit is not convincing 
[166]. 
2.5.4 Heat Exchangers 
Heat exchangers control body temperature by changing the temperature of blood passing through 
the perfusion circuit. Hypothermia is preferred in cardiovascular surgery in order to reduce oxygen 
demand. Gases are more soluble in cold blood so rapid rewarming of cold blood may cause 
formation of bubbles therefore gas emboli [167]. Most membrane oxygenator circuits incorporate a 
heat exchanger upstream to the oxygenator to minimize bubble emboli. Blood is not heated over 
40°C to prevent denaturation of plasma proteins, and temperature difference within the body and 
perfusion circuit are limited to 5–10°C to prevent bubble emboli. 
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2.6 ANTICOAGULATION FOR ECMO 
The goal of anticoagulation for ECMO is to adjust such an equilibrium between attenuating platelet 
and thrombin activation to prevent life-threatening thrombosis and providing sufficient clotting to 
prevent excessive bleeding. Furthermore, an accurate device that has an ability to assess the degree 
of anticoagulation is not clinically available. Unidentified macroscopic clots cause a variety of 
thromboembolic events in patients considered adequately anticoagulated [168]. It seems to be that 
the effectiveness of anticoagulation worsens with the duration of ECMO. Monitoring for 
anticoagulation is the heart beat of ECMO management. The most popular test to monitor 
anticoagulation is the activated clotting time (ACT) and ACT still remains the predominant test to 
manage heparin anticoagulation during ECMO. It measures the integrity of the intrinsic coagulation 
and common pathways. However, the ACT’scapability to correctly measure the level of 
anticoagulation has been questioned [169]. The concerns about ACT’s accuracy are: test results are 
affected by coagulopathy, maturity of coagulation system, platelet dysfunction, degree of 
hypothermia, antithrombin level, age, haemodilution, sample size, and temperature [170,171]. 
Ongoing synthesis of thrombin is another problem especially in children and may result in 
inadequate anticoagulation despite high levels of ACT [171–173]. The popular range for the ACT 
with heparin during ECMOhas been 180–220 s [174]. Baird et al. analysed 604 consecutive 
paediatric ECMO patients retrospectively for factors that affected outcome [170]. The mean ACT 
for all patients was 227 ± 50 s but the range of 158–620 s was very broad. They suggested that 
increased heparin dosing increases survival. The measurement of heparin concentration is an option 
to manage anticoagulation. Laboratory derived heparin concentration is the gold standard but is not 
easily or quickly obtained for patients on. The Hepcon (MedtronicPerfusion Systems, Minneapolis, 
MN) is able to provide heparin concentrations that have relatively good correlation to the laboratory 
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derived anti-Xa plasma heparin measurements [175] and has demonstrated superior results 
compared with ACT [174]. More importantly, unlike the ACT, use of heparin concentrations have 
the benefit of being less sensitive to changes in the patient’s platelet and clotting factor levels. 
However, studies of heparin concentration monitoring for anticoagulation during ECMO are few 
compared to the ACT so target heparin levels have not been determined. Several centres used 
viscoelastic tests, such as thromboelastogram (TEG/ROTEM) [176]. The TEG/ROTEM is a device 
that measures the viscoelastic properties of the blood to examine the whole clotting system instead 
of isolated parts. It provides ongoing coagulation profiles looking at not only the initiation of 
clotting but also the strength and dissolution of the clot as in the case of fibrinolysis. The activated 
partial thromboplastin time (APTT) is universally recognised as a standard monitor for heparin 
therapy except when high heparin dosing is required as in CPB. In situations that do not require 
high heparin dosing, such as ECMO, the APTT is a valuable tool to assess anticoagulation. In a 
comparison between laboratory APTT and ACT, theACT was found to correlate poorly with the 
APTT [168]. Furthermore, in very ill patients requiring continuous heparin infusion, ACT could not 
delineate between low and moderate levels of anticoagulation compared with the APTT[177]. The 
APTT that will prevent thrombus extension with heparin has been reported as 1.5 times baseline 
APTT [178]. This APTT corresponds to a heparin level of 0.2–0.3 u/mL and does not correlate 
moderately well with heparin concentrations [179] .Heparin-continues to be the first choice for 
ECMO because it is rapidly acting, easily reversible, cheap, easily available, and well tolerated by 
paediatric and adult patients. Biologic activity varies between 30 min and six hours depending on 
the systemic heparin concentration. Heparin dosing for adults and paediatric patients is different for 
several reasons. The larger blood volume/weight ratios in neonates compared with adults require 
greater heparin dosing [168]. The more rapid metabolic rates with neonates and infants may allow 
greater excretion by the kidneys and therefore affects heparin dosing. Differences between adults 
and paediatric patients may also derive from the differences in thrombin generation. Traditionally 
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heparin dosing ranges between 20 and 70 U/kg/h for ECMO. Most agree that the APTT should be 
1.5–2.5 times the control. The most recent studies of heparin concentrations suggest a value 0.3–0.7 
u/mL[179]. Heparin dosing for an effective anticoagulation is closely connected with antithrombin 
concentration. Reduced heparin responsiveness is called heparin resistance and for effective 
inhibition of thrombin, adequate levels of antithrombin are required. It is clear that prolonged 
durations of ECMO will lead to consumption of antithrombin and the patient may not be capable of 
maintaining the level. Koster et al., used bivalirudin, a direct thrombin inhibitor, in a patient with 
myocardial failure after repair of acute type A aortic dissection who developed acute heparin-
induced thrombocytopaenia during ECMO and achieved successful results in terms of postoperative 
blood loss and transfusion requirements [180]. 
75 
 
 
2.7 MANAGEMENT OF ECMO: Maintenance and Weaning of ECMO 
Achieving the suggested range of anticoagulation and cannulation, ECMO is commenced by 
unclamping the circuit and slowly increasing flows to the target range. Standard initial settings and 
goals for ECMO are specified in literature and listed in Figure 6 [87,181]  
 
Figure 6: Gokhan Lafc et al. 
 
The basic function of VA-ECMO in supplying mechanical circulatory support is to drain blood 
from the venous circulation, oxygenate it and then return it to the arterial circulation at physiologic 
perfusion pressures. Although ECMO does a very good job of unloading the right ventricle, it does 
not do as good a job of unloading the left ventricle, even though left ventricular preload is 
significantly reduced by the diminished return from the lungs. For this reason, attempts to improve 
left ventricular  contractility, reducing left ventricular distension and clot formation are of utmost 
importance. Such measures should include inotropic support and may include intra-aortic-balloon 
pumping (IABP). Another option in central ECMO is to insert a left ventricular vent to empty the 
ventricle, splicing this line into the venous line of the ECMO circuit. In peripheral ECMO however, 
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the use of an IABP can be detrimental as the peripheral arterial flow from the femoral arterial 
cannula will be competing with the inflated state of the IABP. ECMO flow can be very volume 
dependent and will drop with hypovolaemia, cannula malposition, pneumothorax and pericardial 
tamponade. This usually manifests as ‘kicking’ or ‘chatter’ of the venous tubing as well as a drop in 
output. Management includes a volume challenge, exclusion of intra-abdominal distension or 
compartment syndrome, cardiac tamponade or pneumothorax. If this does not work, a slight 
reduction in flows may be helpful or there may be a need to insert another venous cannula. Further, 
centrifugal pumps in contrast to roller pumps are very afterload dependent and therefore 
hypertension is another variable that can reduce flows and should be avoided. Whilst on ECMO, the 
aim is to support and rest the heart and/or lungs. From a respiratory point of view, hypoxia is treated 
by increasing the flow rate and FiO2 of the ECMO circuit, not by altering the FiO2 and PEEP on the 
ventilator. Attempts should be made to wean the FiO2 on the ventilator and maintain a PEEP level 
of 5–10 cmH2O. A protective lung ventilation strategy with low plateau pressures and low tidal 
volumes should be aimed for as well as low respiratory rates, unless trying to wean off the ECMO 
circuit. PCO2 control should be via the ECMO fresh gas flow to the oxygenator, not by altering the 
respiratory rate on theventilator. From a cardiac point of view the aim should be to minimise the use 
of inotropes and thus rest the heart. However, often a low-dose inotrope infusion is maintained to 
ensure some contractility and adequate emptying of the left ventricle. It is also important to ensure 
the patient is not hypovolaemic. There are no standardised methods or techniques with regards to 
weaning ECMO. With regards to VV ECMO, the actual ECMO flows do not need to be altered to 
assess native respiratory function—this is done by altering gas flow through the ECMO circuit. The 
patient may be weanable if gas exchange is able to be maintained with a low FiO2 on the 
oxygenator (e.g. <30%) and low fresh gas flow rates into the circuit (e.g. <2 L/min) provided that 
the respiratory rate and PEEP set on the ventilator are not too high (e.g. <25 breaths/min and 
<15cmH2O, respectively).With regards to VA ECMO, factors indicating cardiac recovery and thus 
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a potentially weanable patient include; an increasing blood pressure which may need vasodilators, 
return of pulsatility or increasing pulsatility on the arterial pressure waveform, falling pO2 by a right 
radial arterial line indicating more blood is being pumped through the heart which may be less well 
oxygenated, and falling central venous and/or pulmonarypressures. Assessment of native cardiac 
function is performedby reducing flows in the ECMO circuit which requires changes to the 
ventilator and oxygenator gas flow settings, and an increased dose of heparin due to the increased 
risk of stasis and thrombosis at low ECMO flows. A trans oesophageal echocardiogram (TOE) is 
also useful to quantify degree of cardiac recovery and assessing response to reduced flow rates. It 
would be reasonable to reduce pump flows in 0.5 L decrements to 2 L/min over 36–48 h watching 
the above variables. Below this flow rate, major concern would exist with clot formation in the 
circuit. The remainder of the wean generally takes place in the operating room under TOE 
observation and then the patient can be decannulated in a surgical setting.It is important to note that 
cardiac outputs from a pulmonary artery catheter are inaccurate in patients on ECMO because most 
of the circulating blood volume is bypassing the pulmonary circulation (and passing through the 
ECMO circuit) [182]. 
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2.8 COMPLICATIONS OF ECMO 
Not surprisingly, ECMO does have an attendant myriad of possible complications. Complications 
of ECMO are classified as mechanical or patient related (Figure 7). 
 
Figure 7: Gokhan Lafc et al. 
 
With regards to circuit complications, gas embolism and catastrophic blood loss (tubing rupture, 
disconnection) are acutely life-threatening. With centrifugal pumps, a large negative pressure (up to 
100 mmHg) is generated between the drainage cannula and the pump head [87]. Mostly air enters 
from this part of the circuit leading to massive gas embolism. The second cause of gas embolism is 
cavitation. Loss or reduction of circuit flow is a frequent complication usually caused by 
hypovolaemia. The other causes are cardiac tamponade, tension pneumothorax, and cannula 
malposition. 
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With regards to patient complications, haemorrhage, particularly from cannulation and surgical 
sites is the most frequent complication, which can rapidly become life-threatening. Less common, 
but potentially more serious, is gastrointestinal, tracheostomy, and intracranial bleeding. 
Haemorrhage appears to be out of proportion to the degree of coagulopathy and patient platelet 
count. ECMO is well known to cause coagulopathy. Causes of coagulopathy include heparin, 
thrombocytopaenia, fibrinolysis, uraemia and hepatic dysfunction [87]. Continuous activation of the 
contact and fibrinolytic systems by the circuit as well as consumption and dilution of factors occur 
within minutes of initiation of ECMO [163]. The duration of ECMO is very important by means of 
haematologic complications.  
Haemolysis is another well-recognised complication of ECMO with an incidence between 5% and 
8% [183].Thromboembolism, caused by thrombus formation within the extracorporeal circuit is an 
infrequent but serious complication, and is more likely to occur with VA than VV ECMO, because, 
with the latter, the oxygenated blood is returned to the systemic arterial circulation. In addition, 
aortic thrombosis has been described when blood flows retrograde towards the heart (oxygenated 
blood is returned to the systemic circulation via femoral arterial access in peripheral ECMO), and 
stagnates there in the setting of low left ventricular output [184]. Local complications, particularly 
at the site of peripheral insertion of VA-ECMO can occur, of which the most concerning is leg 
ischaemia. A down-flow cannula into the superficial femoral artery can be inserted during 
percutaneous cannulation of the common femoral artery. In open procedures, a Dacron graft can be 
sutured onto the common femoral artery and the cannula inserted into the graft without 
compromising the artery [185]. Fasciotomy for severe leg ischaemia can be required in 6% of the 
patients [186]. Another patient complication is infection. Infection occurs more frequently in 
ECMO patients than other surgical intensive care unit patients. However, sites of infection 
(bloodstream, lower respiratory tract, urinary tract, wound) and causative microorganisms (gram-
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negative bacilli and staphylococci) are similar [187]. Patients who suffer from post-cardiotomy 
cardiogenic shock are more vulnerable to nosocomial infections than other ECMO patients [188]. 
Haemodynamic instability can be seen in both ECMO modalities with different causes. VA ECMO 
totally supports the circulation, so hypotension during VA ECMO implies reduced vascular tone. 
VV ECMO does not have any direct effect on haemodynamics, so hypotension during VV ECMO 
may be caused by reduced vascular tone, reduced preload, or cardiac dysfunction. Severe sepsis can 
lead to marked hypotension and venous desaturation, despite full VA ECMO support. LV distention 
may occur during VA ECMO, particularly in patients with mitral and aortic valve regurgitation. The 
complication is often identified by the presence of alveolar oedema on the chest radiograph or 
oedema fluid frothing up the endotracheal tube shortly after the institution of ECMO. Increasing 
pump flows reduces pulmonary blood flow and may ameliorate this problem. Failing this, the left 
heart must be vented, either surgically or in the catheter laboratory by percutaneous atrial 
septostomy [189]. Fatal arrhythmias can be seen due to electrolyte imbalance or hypoxaemia. 
Hypoxaemia is another patient complication. VA ECMO, usually provides adequate SaO2. But, the 
presence of significant left ventricular ejection and impaired lung function can result in upper-body 
hypoxaemia. This situation most commonly occurs when VA ECMO is inappropriately used for 
treating isolated respiratory failure or when VA ECMO has been used appropriately for cardio-
respiratory failure and cardiac function has recovered. The most common cause of hypoxaemia 
during VV ECMO is inadequate circuit flow. The other causes include sepsis, inadequate sedation, 
iatrogenic overheating, overfeeding, seizures, or recirculation. The most common neurologic 
complication associated with ECMO is intracranial haemorrhage. The reported incidence varies 
between 1.6% and 18.9% [190-193]. The other neurologic complications are ischaemic stroke and 
seizures [193]. Intracranial haemorrhage and/or ischaemic stroke occur due to systemic 
heparinization, thrombocytopaenia, the ligation of carotid artery and jugular vein, coagulopathy or 
systemic hypertension. Renal failure is another complication that is not uncommon. Oliguria is 
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frequently seen in the early stages of ECMO. Acute tubular necrosis may require haemofiltration or 
haemodialysis. 
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2.9 OUTCOMES OF ECMO 
The results of ECMO support are fairly consistently related to the indication for institution of such 
therapy.  
The Extracorporeal Life Support Organization (ELSO) established in 1989 and located at the 
University of Michigan, maintains a registry of all known cases in which ECMO was used. Over 
250 international centres have contributed data to the registry. Currently there are over 65,000 cases 
in the Registry including over 34,000 newborns, 16,000 children and 14,000 adults. In the adult 
population (>18 years), 7,008 cases of ECMO support for respiratory failure were reported of which 
57% survived to discharge. 5,603 patients were supported for cardiac failure of which only 41% 
survived to discharge. A separate category of patients requiring urgent deployment of ECMO for 
established or impending cardiopulmonary arrest are presented in the report. Of the 639 cases 
reported 28% survived to discharge (Figure 8). 
Unfortunately, good quality randomised controlled trials of ECMO outcomes in the adult 
population are lacking. 
 
2.10 CONCLUSIONS 
Although controversial, ECMO may be of benefit in selected adult patients with cardiopulmonary 
failure. Due to its complexity, patients requiring ECMO are best served in centers which use this 
technique regularly. However, all intensivists should be familiar with the principles and methods of 
ECMO both to optimize its use and also to facilitate education for staff, patients, and families. 
83 
 
 
 
Figure 8: ELSO REGISTRY 
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3. EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN REFRACTORY 
CARDIOGENIC SHOCK: IMPACT OF ACUTE VERSUS CHRONIC ETIOLOGY ON 
OUTCOME 
 
3.1 INTRODUCTION 
Acute cardiogenic shock is a condition that continues to have a very high mortality despite 
advances in medical therapy [1-3]. Conventional treatment typically comprises inotrope infusions, 
vasopressors and intra-aortic-balloon-pump (IABP) [1, 4]. When circulatory instability is refractory 
to these treatments, mechanical circulatory support represents the only hope for survival, as 
indicated by current guidelines [3, 4]. As most of these patients present with critical circulatory 
instability requiring urgent or emergent therapy, the chosen mechanical assistance should be rapidly 
and easily implanted. For this reason ExtraCorporeal Membrane Oxygenation (ECMO) represents 
the ideal “bridge-to-life” and increasingly it is used to keep the patient alive while the optimal 
therapeutic management is determined (bridge-to-decision). Management may then follow one of 
three courses: “bridge-to-recovery”: patient recovery, and weaning from ECMO; “bridge-to-
transplant”: direct orthotopic heart transplantation; “bridge-to-bridge”: placement of ventricular-
assist-device or total artificial longer-term support [5, 6] There have been several large reports on 
the use of ECMO as a mechanical support in post-cardiotomy patients [3,7-9] but relatively few, 
mostly small case-series focusing on its role in primary acute cardiogenic shock outside of the post-
cardiotomy setting [10-13]. 
 We present the results of our centre’s experience (Padova) in the treatment of primary acute 
cardiogenic shock with the PLS-Quadrox ECMO system (Maquet) as a bridge to decision. 
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Furthermore, we evaluated the impact of etiology on patient outcomes by comparing acute primary 
refractory CS secondary to acute myocardial infarction (AMI), myocarditis, pulmonary embolism 
(PE) and post-partum cardiomyopathy (PPCM) with acute decompensation of a chronic 
cardiomyopathy, including dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM) and 
grown-up-congenital-heart-diseases (GUCHD). We also analyzed whether duration and magnitude 
of support may predict weaning and survival. 
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3.2 MATERIALS AND METHODS 
3.2.1 Patients 
Between January 2009 and March 2013, a total of 249 patients were treated with ECMO in our 
center. We prospectively analyzed 64 patients implanted with the PLS
TM
 ECMO system for 
treatment of cardiogenic shock refractory to maximal inotropic and vasopressor therapy and IABP, 
excluding postcardiotomy, pediatric and respiratory supports. We divided patients in two groups 
according to etiology: 37 were assigned to the “Acute” group (A-PCS), where the primary cause 
was an acute event in a previously healthy heart, including 26 AMI, 4 myocarditis, 6 PE, 1 post-
partum cardiomyopathy; 27 to the “Chronic” group (C-PCS), in whom the etiology was an acute 
deterioration of a chronic cardiomyopathy, including 20 DCM, 5 ICM, 2 GUCHD (Table 1). 
Written informed consent was obtained for all patients. 
Table 1. Etiologies leading to ECMO implantation, in the overall population, A-PCS group, 
and C-PCS group. 
Etiology Overall (n=64) A-PCS (n=37) C-PCS (n=27) 
AMI 26 (41%) 26 (70%) 0 
Myocarditis 4 (6%) 4 (11%) 0 
Pulmonary embolism 6 (9%) 6 (16%) 0 
Post-partum CM 1 (2%) 1 (3%) 0 
DCM 20 (31%) 0 20 (74%) 
ICM 5 (8%) 0 5 (19%) 
Congenital 2 (3%) 0 2 (7%) 
AMI: acute myocardial infarction; CM: cardiomyopathy; DCM: dilated CM; ICM: ischemic CM. 
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3.2.2 Criteria for ECMO installation 
Patients who met the criteria of profound CS due to pump failure were candidates for ECMO. 
Profound shock was defined as systolic blood pressure less than 75 mm Hg, cardiac index ≤ 1.8 
L/minute/m
2
, with left ventricular end-diastolic pressure >20 mmHg, despite receiving multiple 
high-dose intravenous inotropic agents (dopamine ≥10 µg/kg/minute, dobutamine ≥10 
µg/kg/minute, epinephrine ≥0,1 µg/kg/minute, norepinephrine ≥0,1 µg/kg/minute) and/or IABP, 
associated with clinical signs of pulmonary congestion, and impaired end-organ perfusion (renal, 
respiratory and hepatic failure and altered mental status) [14]. The diagnosis of impaired end-organ 
function required at least one of the following: altered mental status; cold, clammy skin and 
extremities; oliguria with urine output of less than 30 ml per hour; respiratory failure was defined as 
PaO2 <60 mmHg and/or PaCO2 >45 mmHg (type I-II) or need for mechanical ventilation in the 
setting of cardiogenic shock (type IV); serum lactate level higher than 2.0 mmol per liter; bilirubin 
or transaminases > three times the upper normal limit set by the local laboratory; multi-organ-
failure (MOF) was defined as failure of two or more organs, in addition to cardiac dysfunction. 
[4,15] The only absolute contraindication to ECMO was the presence of severe neurologic 
involvement after arrest (significant anisocoria and signs of decerebration or focality); age > 75 
years and severe peripheral vascular disease (PVD) were considered relative contraindications. [6] 
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3.2.3 ECMO system 
The system used in our institute was the PLS
TM
 ECMO (Maquet, Cardiopulmonary AG, Hirrlingen, 
Germany) [7,16]. This system has a portable, “all-in-one” design including oxygenator (Quadrox 
D
TM
), centrifugal pump (Rotaflow
TM
), and heparin-coated tubes as well as an optional heat 
exchanger, with specific features to minimise thrombotic risk [7,16]. Furthermore it has obtained 
CE approval for 14 days of support.  
 
3.2.4 ECMO placement 
In our institute, when feasible, we opted to implant ECMO with the patient awake and breathing 
independently, with local anaesthetic, at the bedside. Cannulation was performed using a 
percutaneous veno-arterial Seldinger technique, with venous drainage cannula placed in the femoral 
vein (18F to 28F) and arterial return cannula placed in the femoral artery (18F to 22F). When this 
strategy was unsuccessful or contra-indicated (eg. significant peripheral vascular disease, small 
femoral vessels) the patient was taken to theatre, sedated and intubated. At the surgeon’s discretion, 
a choice between one of the following cannulation techniques was made: subclavian or inguinal 
dissection and anastomosis of an 6 to 10 mm Dacron vascular graft onto the subclavian or femoral 
artery for cannulation, or, in a single case, sternotomy and central cannulation (venous cannula in 
right atrium and arterial cannula in ascending aorta). Limb ischemia subsequent to percutaneous 
femoral arterial cannulation was dealt with distal cannulation using a smaller cannula (either 
percutaneous or surgical) or by shifting the cannulation site. 
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3.2.5 Anticoagulant management 
Before placement of cannulae, a heparin bolus of 70 U/Kg (usually 5000 units) was administered to 
obtain an ACT of 180 s. We then performed aPTT, INR and antithrombin assays 4 times per day 
and platelet counts, fibrinogen and d-dimer assays once daily. Patients were kept anticoagulated 
with heparin maintaining and aPTT in the range of 50 – 60 sec. When d-dimer was elevated or there 
were haemorrhagic or thrombotic complications, a thromboelastometry was carried out and targeted 
therapy, based on these results, was commenced. 
 
3.2.6 Management of ECMO 
ECMO is intended as a bridge-to-life, and at first all patients need full-flow support (patient’s 
estimated required cardiac output (CO), calculated as BSA*2.4 l/min). In this phase stabilization is 
obtained, with cardiac function totally replaced by ECMO, which guarantees circulatory support 
and organ perfusion.  
After this phase, some pulsatility may be observed, and this would be a sign of an initial recovery of 
cardiac function. In this second phase, we maintain inotropic support and IABP when already 
present prior to ECMO implantation; we wake the patient to guarantee sympathetic tone; we 
perform weaning from mechanical ventilation, achieving extubation as soon as possible, to reduce 
pulmonary resistance; we start to reduce support, monitoring pulsatility and organ perfusion 
(lactate, urine output, central venous pressure, pulmonary capillary wedge pressure). We maintain 
inotrope therapy, to help the native heart to open the aortic valve and empty the left ventricle (LV), 
thus eliminating the need for a vent. If the patient remains stable, the third phase is commenced, 
which consists of a weaning protocol. 
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3.2.7 Weaning trial 
After obtaining hemodynamic stabilization and improvement of organ function (either neurologic, 
respiratory, renal and hepatic), ECMO support was progressively decreased to 1 L per minute. 
Standard management involved serial echocardiograms during this phase, but we mostly relied on 
persistence of satisfactory hemodynamics and organ function on low-to-medium dose inotropic 
support, to assess the feasibility of weaning from ECMO. In detail, we performed 
echocardiographic evaluation of ventricular function (LV EF >35%, good RV contractility) and 
volume (absence of excessive ventricular distension, or severe tricuspid regurgitation), as well as 
clinical parameters such as normal systemic pressure (systolic >85mmHg) and central venous 
pressure, normal blood lactate level and urine output.  
 
3.2.8 Data Analysis 
Continuous variables are expressed as means ±SD, median (range). Categorical variables are 
summarized by reporting absolute frequency distribution and percentage, and were compared using 
the χ2-test or Fisher’s exact test as appropriate. Student t test (for unpaired data) or the Mann-
Whitney test were used to compare continuous variables, as appropriate (normal distribution was 
assessed by the Shapiro-Wilk normality test). Overall survival and survival after discharge were 
estimated by the Kaplan-Meier method. Statistical findings were considered significant if the 
critical level was less than 5% (p<.05). Statistical analysis was performed using STATA software 
(release 10.0 for Windows; Stata Corporation LP, College Station, Tex).  
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Table 2. Preoperative characteristics. 
Preoperative 
characteristics 
Overall 
(n=64) 
A-PCS 
(n=37) 
C-PCS 
(n=27) 
p 
(A vs C) 
Age (y) 50 ± 16 52 ± 15 48 ± 17 0.38 
Sex (female) 12 (19%) 10 (27%) 2 (7%) 0.004 
BSA (m
2
) 1.8 ± 0.2 1.9 ± 0.2 1.8 ± 0.1 0.001 
Malignant arrythmia 29 (45%) 18 (49%) 11 (41%) 0.04 
CPR within 72h 32 (50%) 26 (70%) 6 (22%) <0.0001 
N. of inotropes 1.9 ± 1 1.7 ± 1 2.1 ± 1.1 0.009 
IABP 25 (39%) 19 (51%) 6 (22%) 0.001 
Respiratory failure 55 (86%) 32 (86%) 23 (85%) 0.04 
Mechanical 
ventilation 
46 (72%) 29 (78%) 17 (63%) 0.01 
Renal failure 32 (50%) 14 (38%) 18 (67%) 0.001 
CVVH 8 (13%) 4 (11%) 4 (15%) 0.71 
Hepatic failure 20 (31%) 7 (19%) 13 (48%) 0.0007 
MOF 24 (38%) 12 (32%) 12 (44%) 0.32 
APACHE IV score - 
predicted mortality 
61% ± 16% 58% ± 16% 65% ± 17% 0.38 
 
113 
 
3.3 RESULTS 
Preoperative characteristics, implantation technique, mechanical support data and outcomes are 
reported in Tables 2, 3, 4 and 5 respectively. Mean age was 50 ± 16 years with no differences 
between A-PCS and C-PCS groups. In A-PCS group there was a higher incidence of malignant 
arrhythmias (A-PCS: 49% vs C-PCS: 41%), CPR either in the previous 72 hours (A-PCS: 70% vs 
C-PCS: 22%) or during ECMO implantation (A-PCS: 38% vs C-PCS: 11%), IABP (A-PCS: 51% 
vs C-PCS: 22%), and mechanical ventilation (A-PCS: 78% vs C-PCS: 63%). In C-PCS group we 
observed a greater rate of end-organ dysfunction, demonstrated by the higher number of inotropes 
(C-PCS 2.1 vs A-PCS 1.7), renal (C-PCS 67% vs A-PCS 38%) and hepatic failure (C-PCS 48% vs 
A-PCS 19%).  The Acute Physiology and Chronic Health Evaluation (APACHE) IV score indicated 
a 61% ±16% predicted mortality, with no differences between the two groups (Table 2). 
Table 3. Implantation technique. 
Implantation technique Overall (n=64) A-PCS (n=37) C-PCS (n=27) P (A vs C) 
Bedside 31 (48%) 21 (57%) 10 (37%) 0.11 
Salvage CPR 17 (27%) 14 (38%) 3 (11%) 0.02 
Peripheral F-F 51 (80%) 32 (86%) 19 (70%) 0.11 
Peripheral S-F 12 (19%) 4 (11%) 8 (30%) 0.1 
Upgrade F-F to S-F 9 (14%) 4 (11%) 5 (19%) 0.48 
Central 1 (1%) 1 (3%) 0 0.04 
BSA: body surface area; CPR: cardio-pulmonary-resuscitation; CVVH: continuous-veno-venous 
hemofiltration; F-F: femoro-femoral; IABP: intra-aortic-balloon-counterpulsation; MOF: multi-
organ-failure; S-F: subclavian-femoral. 
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V-A ECMO was implanted peripherally in 
all but one case. Fifty-one patients were 
treated with F-F cannulation, and 12 with S-
F ECMO. Nine patients required shifting of 
cannulation site from femoral to subclavian 
artery, because of limb ischemia or issues in 
femoral cannulation (Table 3).  
Mean duration of ECMO support was 9±9 
days (range, 1–46), with no differences 
between the two groups. Mean percentage of 
theoretical flow was 61 ±15%. Patients in C-
PCS group required higher support compared 
with A-PCS (67% vs 57%) to achieve 
adequate organ perfusion, as confirmed by 
the absence of difference in serum lactates 
(expressed as the average of the peak lactate 
on a daily basis). As expected, given the 
greater frequency of AMI in the A-PCS 
group, peak troponin was significantly 
greater in this group (Table 4). The outcomes 
of ECMO support differed significantly 
between the two groups. In C-PCS group, 23 patients were bridged to either a left-ventricular-assist-
device (52%) or heart-transplantation (33%). Conversely, in A-PCS group ECMO was used as 
bridge-to-transplantation in 3 patients (8%), bridge-to-bridge in 9 patients (24%), and bridge-to-
Figure 1: Analysis of support duration vs: (A) mortality on 
ECMO (p=0.06); (B) 30-day mortality (p=0.05)]; (C) 
survival to discharge (p=0.002). 
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recovery in 18 patients (49%). One patient in both groups was bridged to conventional surgery. 
Recovery of cardiac function was achieved only in A-PCS group (18 vs 0 pts, p=0.0001). In terms 
of mortality during ECMO support (16% in A-PCS vs 11% in C-PCS), hospital discharge (59% in 
A-PCS vs 56% in C-PCS) and survival at 4-years follow-up (49% in group A-PCS vs 44% in C-
PCS), the two groups were comparable; only 30-day mortality differed between the groups being 
significantly greater in the C-PCS group (26% in C-PCS vs 16% in A-PCS, p=0.02). (Table 5). 
Complications during support were similar in the two groups (Table 6).  
 
Table 4. Details of ECMO support. 
Parameter 
Overall 
(n=64) 
A-PCS (n=37) 
C-PCS 
(n=27) 
p (A vs C) 
Duration (days)* 7 (2-11.5) 7 (2.75-10.25) 7 (2-12.75) 0.86 
Flow (% of theoretical CO) 61 ±15 57 ±13 67 ±15 0.004 
N. of inotropes (mean) 2.6 ±1.1 2.2 ±1.1 3.1 ±0.8 <0.001 
Serum lactates (mmol/L)* 
2.55  
(1.7-3.6) 
2.3 
 (1.55-3.25) 
2.85 
 (1.9-4.3) 
0.14 
TnI peak (μg/L)* 
3.75  
(0.33-100) 
53 
 (2.2-231.9) 
0.47  
(0.15-1.98) 
0.0007 
Legend: CO: cardiac output . *median (IQR) 
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Table 5.  Outcomes of ECMO support. 
Outcome 
Overall 
(n=64) 
A-PCS 
(n=37) 
C-PCS (n=27) p (A vs C) 
BTD 9 (14%) 6 (16%) 3 (11%) 0.72 
BTR 18 (28%) 18 (49%) 0 <0.0001 
BTS 2 (3%) 1 (3%) 1 (4%) 0.04 
BTB 23 (36%) 9 (24%) 14 (52%) 0.001 
BTT 12 (19%) 3 (8%) 9 (33%) 0.001 
Mortality in ECMO 9 (14%) 6 (16%) 3 (11%) 0.72 
Mortality 30-day 13 (20%) 6 (16%) 7 (26%) 0.02 
Discharged from hospital 37 (58%) 22 (59%) 15 (56%) 0.75 
Legend: BTD: bridge-to-decision; BTR: bridge-to-recovery; BTS: bridge-to-conventional surgery; 
BTB: bridge-to-bridge; BTT: bridge-to-transplant. 
 
Analysis of support duration revealed that duration tends to affect mortality on ECMO and also at 
30 days [Figure 1A (p=0.06); figure 1B (p=0.05)], and is a significant predictor of hospital 
discharge (Figure 1C, p=0.002). We have also shown that a support duration of less than 8 days 
predicts improved outcomes [mortality in ECMO (p=0.05), 30-day mortality (p=0.01), hospital 
discharge (p=0.002)]. Analysis of flow rates has demonstrated that in the A-PCS group, the required 
percent of support is a significant predictor of recovery [Figure 2A (p=0.03)]. In fact, we have 
shown that flow rates less than 60% correlate with probability of recovery (p=0.02). A subgroup of 
particular interest is represented by patients suffering AMI, in whom this phenomenon is 
particularly accentuated [Figure 2B (p=0.01)] (Figure 2). 
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Table 6. Complications  during ECMO support. 
Complications during 
ECMO 
Overall 
(n=64) 
A-PCS 
(n=37) 
C-PCS 
(n=27) 
p (A vs C) 
Neurological 12 (19%) 8 (22%) 4 (15%) 0.49 
Limb ischemia 9 (14%) 6 (16%) 3 (11%) 0.72 
Leg amputation 0 0 0 1.00 
Bleeding 13 (20%) 8 (22%) 5 (19%) 0.76 
Hemolysis 1 (2%) 1 (3%) 0 1.00 
Renal failure 25 (39%) 12 (32%) 13 (48%) 0.20 
CVVH 22 (34%) 10 (27%) 12 (44%) 0.14 
Oxygenator change 14 (22%) 5 (14%) 9 (33%) 0.06 
Malfunction 4 (6%) 2 (5%) 2 (7%) 1.00 
ARDS/Pulmonary congestion 5 (8%) 1 (3%) 4 (15%) 0.15 
Sepsis 9 (14%) 3 (8%) 6 (22%) 0.15 
MOF post 14 (22%) 8 (22%) 6 (22%) 0.95 
Legend: ARDS: acute respiratory distress syndrome; CVVH: continuous veno-venous 
hemofiltration; MOF: multi-organ-failure. 
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Overall survival did not differ between the 
two groups (A-PCS 73% vs C-PCS 70% at 1 
month, A-PCS 57% vs C-PCS 56% at 6 
months, A-PCS 51% vs C-PCS 55% at 1 and 
4 years) (Figure 3A). The overall actuarial 
survival of the cohort after discharge was 
89% at 1-year and 86% at 4-year follow-up 
(Figure 3B). A result of particular interest 
was the survival of those patient who 
recovered cardiac function, which was 83% 
at 4-years follow-up (Figure 3C).
Figure 2: Analysis of mean flow vs. (A) recovery in A-
PCS group (p=0.03); (B) recovery in AMI group (p=0.01). 
Figure 3: Kaplan-Meier estimates of actuarial survival 
in different populations: (A) overall; (B) discharged 
patients; (C) bridge-to-recovery subgroup after 
discharge. 
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3.4 COMMENT 
The aim of this study was to evaluate the impact of etiology – in particular acute vs chronic – on the 
outcome of patients in acute cardiogenic shock treated with ECMO. 
The outcomes assessed were death during ECMO support, 30-day mortality, hospital discharge, 
survival at follow-up, both overall and in the two aetiology groups. The two groups were 
comparable in terms of their pre-implantation condition and post-implantation complications. 
Differences between the groups could be attributed to the differing etiology of cardiogenic shock: in 
the chronic group, shock represents the end-stage of a progressive decline in cardiac function with 
chronic structural damage, a picture not seen in group A-PCS, where the most common cause of 
cardiogenic shock was AMI. In the analysis of primary end points the only difference between the 
groups was the greater 30-day mortality in the chronic group when compared to the acute group. 
This data is consistent with the recent series published by Bermudez et al [6], but differs regarding 
long-term survival. Indeed in our series the two groups were comparable in terms of mortality 
during support, hospital discharge and even survival at follow-up. When considering all patients, 
the outcomes are in line with the existing literature, as is overall survival [13,18]. In light of these 
results it is possible to say that the use of ECMO allows survival to be maximized in patients who 
are otherwise untreatable and face an extremely severe prognosis, independent of etiology of the 
shock and hence also their study group. Indeed, in our experience, unlike Bermudez et al [6], 
patients in a chronic setting can also benefit from ECMO as a bridge to candidacy for VAD or 
transplant.  
As secondary end points we have looked at the proportion of patients who had recovery of cardiac 
function (bridge-to-recovery) to determine if the duration and magnitude of support are predictors 
of recovery and survival.  
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In keeping with the markedly different profiles of the two groups, was the fact that the recovery 
occurred only within the acute group. This difference was highly significant and reinforced the idea 
that cardiogenic shock, in the context of chronic progressive cardiac failure, represents the terminal 
stage of the disease which is not possible to remedy without replacing the heart’s pump function. As 
a result, in group C-PCS, ECMO acted essentially as either a bridge to VAD  or bridge-to-
transplant. Conversely in group A-PCS, ECMO support temporarily rests the damaged myocardium 
allowing it to recover functionality [19]. In patients with refractory shock secondary to an acute 
aetiology ECMO offers a substantial chance of recovery, often representing, after failed PCI, the 
only therapy required.  
In patients with the best outcomes in terms of mortality during support and at 30 days, the duration 
of ECMO was significantly inferior; the same relationship was seen in hospital discharge: 
specifically a duration of support of less than 8 days is a significant predictor of improved chance of 
survival and hospital discharge. Potentially the shorter duration of support reflects, at least partly, a 
less substantial systemic compromise. 
Another part of this study is related to the management of the flow rates. In our experience, after the 
first phase of “resuscitation” at full-flow, we aimed to reduce the support, whenever possible. 
Specific strategies make this possible. Firstly, the use of ECMO reduces venous return and hence 
the preload of the LV, thus reducing the work it is required to do. Secondly, ECMO provides most 
of the splanchnic circulation, while not increasing the afterload on the left ventricle as much as full 
support would. Finally, with the help of inotropes, the native heart is often able to open the aortic 
valve and emptying the left ventricle (LV), thus eliminating the need for a vent, and also providing 
most of the coronary and cerebral perfusion. Within the acute group, analyses of flow rates 
demonstrate that the maintenance of support at <60% of theoretical requirement was significantly 
associated with recovery of cardiac function, likely reflecting a less severe initial myocardial 
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condition and a greater degree of reversibility. Of particular interest within the acute group is the 
subgroup of patients with AMI, both for its epidemiological significance and its high frequency in 
the acute group (n=26). In this subgroup the proportion of patients who recover cardiac function is 
very promising, totaling 42%. These results are comparable to existing literature and in particular to 
studies reporting specifically the results of patients with cardiogenic shock secondary to AMI [18]. 
It is reasonable to propose that in this group ECMO helps to contain the damage caused by 
ischemia-reperfusion injury and evolution of the infarcted area by directly reducing the afterload 
against which the heart has to work and hence reducing the oxygen demand of the myocardium 
[19]. In this subgroup it was also seen that the degree of ECMO support was a predictor of cardiac 
function recovery: patients who experienced recovery had mean flows of 55% of theoretical 
predicted requirement. 
When analysing all patients as a single cohort, an interesting finding was survival both short and 
long term. In our study 30-day survival was around 80% and discharge from hospital was around 
60%. A particularly encouraging result was the 89% survival at 2-years follow-up seen in patients 
discharged from hospital. The subgroup with shock due to AMI was consistent with these findings, 
but peculiar in so far as ECMO was the only necessary treatment after failed PCI for 42% of the 
patients, and provided a long-term survival in the order of 80%. These results would support the use 
of ECMO in PCS, where treatment with IABP was recently shown to confer no benefit in terms of 
mortality [20].  
 
3.5 CONCLUSIONS 
ECMO is intended as a bridge-to-life and should be considered as a first line of support in patients 
with refractory cardiogenic shock. In the setting of a chronic decline in cardiac function, ECMO 
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represents a bridge to implantation of VAD or orthotopic heart transplant. In patients with 
refractory shock due to acute aetiologies, ECMO offers a substantial chance of recovery, often 
representing, after failed PCI, the only necessary treatment. In our experience the magnitude and 
duration of the ECMO support significantly impacts the chance of weaning and also of survival, 
reflecting a less severe initial myocardial condition and a greater degree of reversibility.  
Maintaining flows at around 60% of the theoretical requirement and minimising the duration of 
support appears to be the strategy which offers the best chance of survival. 
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